Oxidized	O
alkyl	O
phospholipids	O
are	O
specific	O
,	O
high	O
affinity	O
peroxisome	O
proliferator-activated	O
receptor	O
gamma	O
ligands	O
and	O
agonists	O
.	O

Synthetic	O
high	O
affinity	O
peroxisome	O
proliferator-activated	O
receptor	O
(	O
PPAR	O
)	O
agonists	O
are	O
known	O
,	O
but	O
biologic	O
ligands	O
are	O
of	O
low	O
affinity	O
.	O

Oxidized	B-protein
low	I-protein
density	I-protein
lipoprotein	I-protein
(	O
oxLDL	B-protein
)	O
is	O
inflammatory	O
and	O
signals	O
through	O
PPARs	B-protein
.	O

We	O
showed	O
,	O
by	O
phospholipase	O
A	O
(	O
1	O
)	O
digestion	O
,	O
that	O
PPARgamma	O
agonists	O
in	O
oxLDL	B-protein
arise	O
from	O
the	O
small	O
pool	O
of	O
alkyl	O
phosphatidylcholines	O
in	O
LDL	B-protein
.	O

We	O
identified	O
an	O
abundant	O
oxidatively	O
fragmented	O
alkyl	O
phospholipid	O
in	O
oxLDL	B-protein
,	O
hexadecyl	O
azelaoyl	O
phosphatidylcholine	O
(	O
azPC	O
)	O
,	O
as	O
a	O
high	O
affinity	O
ligand	O
and	O
agonist	O
for	O
PPARgamma	B-protein
.	O

[	O
(	O
3	O
)	O
H	O
]	O
azPC	O
bound	O
recombinant	B-protein
PPARgamma	I-protein
with	O
an	O
affinity	O
(	O
K	O
(	O
d	O
)	O
(	O
(	O
app	O
)	O
)	O
approximately	O
40	O
nm	O
)	O
that	O
was	O
equivalent	O
to	O
rosiglitazone	O
(	O
BRL49653	O
)	O
,	O
and	O
competition	O
with	O
rosiglitazone	O
showed	O
that	O
binding	O
occurred	O
in	O
the	O
ligand-binding	B-protein
pocket	I-protein
.	O

azPC	O
induced	O
PPRE	O
reporter	O
gene	O
expression	O
,	O
as	O
did	O
rosiglitazone	O
,	O
with	O
a	O
half-maximal	O
effect	O
at	O
100	O
nm	O
.	O

Overexpression	O
of	O
PPARalpha	B-protein
or	O
PPARgamma	B-protein
revealed	O
that	O
azPC	O
was	O
a	O
specific	O
PPARgamma	O
agonist	O
.	O

The	O
scavenger	B-protein
receptor	I-protein
CD36	I-protein
is	O
encoded	O
by	O
a	O
PPRE-responsive	B-DNA
gene	I-DNA
,	O
and	O
azPC	O
enhanced	O
expression	O
of	O
CD36	B-protein
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

We	O
found	O
that	O
anti-CD36	B-protein
inhibited	O
azPC	O
uptake	O
,	O
and	O
it	O
inhibited	O
PPRE	O
reporter	O
induction	O
.	O

Results	O
with	O
a	O
small	O
molecule	O
phospholipid	B-protein
flippase	I-protein
mimetic	I-protein
suggest	O
azPC	O
acts	O
intracellularly	O
and	O
that	O
cellular	O
azPC	O
accumulation	O
was	O
efficient	O
.	O

Thus	O
,	O
certain	O
alkyl	O
phospholipid	O
oxidation	O
products	O
in	O
oxLDL	B-protein
are	O
specific	O
,	O
high	O
affinity	O
extracellular	O
ligands	O
and	O
agonists	O
for	O
PPARgamma	B-protein
that	O
induce	O
PPAR-responsive	B-DNA
genes	I-DNA

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

276	NULL
,	NULL
No	NULL
.	NULL

19	NULL
,	NULL
Issue	NULL
of	NULL
May	NULL
11	NULL
,	NULL
pp	NULL
.	NULL

16015-16023	NULL
,	NULL
2001	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Oxidized	NULL
Alkyl	NULL
Phospholipids	NULL
Are	NULL
Specific	NULL
,	NULL
High	NULL
Affinity	NULL
Peroxisome	NULL
Proliferator-activated	NULL
Receptor	NULL
y	NULL
Ligands	NULL
and	NULL
Agonists*	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
January	NULL
30	NULL
,	NULL
2001	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
February	NULL
23	NULL
,	NULL
2001	NULL
Published	NULL
,	NULL
JBC	NULL
Papers	NULL
in	NULL
Press	NULL
,	NULL
February	NULL
26	NULL
,	NULL
2001	NULL
,	NULL
DOI	NULL
10.1074/jbc.M100878200	NULL
Sean	NULL
S.	NULL
Davies	NULL
}	NULL
§	NULL
,	NULL
Aaron	NULL
V.	NULL
Gopal	NULL
K.	NULL
Marathe1	NULL
]	NULL
,	NULL
Kathleen	NULL
A.	NULL
Harrison**	NULL
,	NULL
Robert	NULL
C.	NULL
Murphy**	NULL
,	NULL
Jerald	NULL
C.	NULL
Hinshaw	NULL
#	NULL
?	NULL

$	NULL
}	NULL
,	NULL
Glenn	NULL
D.	NULL
Prestwich	NULL
#	NULL
?	NULL

#	NULL
,	NULL
Andy	NULL
St.	NULL
Hilaire	NULL
]	NULL
,	NULL
Stephen	NULL
M.	NULL
Prescott|§§	NULL
,	NULL
Guy	NULL
A.	NULL
Zimmerman1	NULL
]	NULL
,	NULL
and	NULL
Thomas	NULL
M.	NULL
From	NULL
the	NULL
Departments	NULL
of	NULL
{	NULL
Pathology	NULL
,	NULL
Internal	NULL
Medicine	NULL
,	NULL
and	NULL
¢	NULL
#	NULL
{	NULL
Medicinal	NULL
Chemistry	NULL
,	NULL
the	NULL
Program	NULL
in	NULL
Human	NULL
Molecular	NULL
Biology	NULL
and	NULL
Genetics	NULL
,	NULL
the	NULL
§§Huntsman	NULL
Cancer	NULL
Institute	NULL
,	NULL
University	NULL
of	NULL
Utah	NULL
,	NULL
Salt	NULL
Lake	NULL
City	NULL
,	NULL
Utah	NULL
84112	NULL
and	NULL
the	NULL
**Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
National	NULL
Jewish	NULL
Medical	NULL
and	NULL
Research	NULL
Center	NULL
,	NULL
Denver	NULL
,	NULL
Colorado	NULL
80206	NULL
Synthetic	NULL
high	NULL
affinity	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
(	NULL
PPAR	NULL
)	NULL
agonists	NULL
are	NULL
known	NULL
,	NULL
but	NULL
biologic	NULL
ligands	NULL
are	NULL
of	NULL
low	NULL
affinity	NULL
.	NULL

Oxidized	NULL
low	NULL
density	NULL
lipoprotein	NULL
(	NULL
oxLDL	NULL
)	NULL
is	NULL
inflammatory	NULL
and	NULL
signals	NULL
through	NULL
PPARs	NULL
.	NULL

We	NULL
showed	NULL
,	NULL
by	NULL
phospholipase	NULL
A	NULL
,	NULL
digestion	NULL
,	NULL
that	NULL
PPARy	NULL
agonists	NULL
in	NULL
oxLDL	NULL
arise	NULL
from	NULL
the	NULL
small	NULL
pool	NULL
of	NULL
alkyl	NULL
phosphatidylcholines	NULL
in	NULL
LDL	NULL
.	NULL

We	NULL
identified	NULL
an	NULL
abundant	NULL
oxidatively	NULL
fragmented	NULL
alkyl	NULL
phospholipid	NULL
in	NULL
oxLDL	NULL
,	NULL
hexadecyl	NULL
azelaoyl	NULL
phosphatidylcholine	NULL
(	NULL
azPC	NULL
)	NULL
,	NULL
as	NULL
a	NULL
high	NULL
affinity	NULL
ligand	NULL
and	NULL
agonist	NULL
for	NULL
PPARy	NULL
.	NULL

[	NULL
°HJazPC	NULL
bound	NULL
recombinant	NULL
PPARy	NULL
with	NULL
an	NULL
affinity	NULL
(	NULL
Kd	NULL
(	NULL
ﬂpp	NULL
)	NULL
~40	NULL
nM	NULL
)	NULL
that	NULL
was	NULL
equivalent	NULL
to	NULL
rosiglitazone	NULL
(	NULL
BRL49653	NULL
)	NULL
,	NULL
and	NULL
competition	NULL
with	NULL
rosiglitazone	NULL
showed	NULL
that	NULL
binding	NULL
occurred	NULL
in	NULL
the	NULL
ligand-binding	NULL
pocket	NULL
.	NULL

azPC	NULL
induced	NULL
PPRE	NULL
reporter	NULL
gene	NULL
expression	NULL
,	NULL
as	NULL
did	NULL
rosiglitazone	NULL
,	NULL
with	NULL
a	NULL
half-maximal	NULL
effect	NULL
at	NULL
100	NULL
ny	NULL
.	NULL

Overexpression	NULL
of	NULL
PPARa	NULL
«	NULL
or	NULL
PPARy	NULL
revealed	NULL
that	NULL
azPC	NULL
was	NULL
a	NULL
specific	NULL
PPARy	NULL
agonist	NULL
.	NULL

The	NULL
scavenger	NULL
receptor	NULL
CD36	NULL
is	NULL
encoded	NULL
by	NULL
a	NULL
PPRE-responsive	NULL
gene	NULL
,	NULL
and	NULL
azPC	NULL
enhanced	NULL
expression	NULL
of	NULL
CD36	NULL
in	NULL
primary	NULL
human	NULL
monocytes	NULL
.	NULL

We	NULL
found	NULL
that	NULL
anti-CD36	NULL
inhibited	NULL
azPC	NULL
uptake	NULL
,	NULL
and	NULL
it	NULL
inhibited	NULL
PPRE	NULL
reporter	NULL
induction	NULL
.	NULL

Results	NULL
with	NULL
a	NULL
small	NULL
molecule	NULL
phospholipid	NULL
flippase	NULL
mimetic	NULL
suggest	NULL
azPC	NULL
acts	NULL
intracellularly	NULL
and	NULL
that	NULL
cellular	NULL
azPC	NULL
accumulation	NULL
was	NULL
efficient	NULL
.	NULL

Thus	NULL
,	NULL
certain	NULL
alkyl	NULL
phospholipid	NULL
oxidation	NULL
products	NULL
in	NULL
oxLDL	NULL
are	NULL
specific	NULL
,	NULL
high	NULL
affinity	NULL
extracellular	NULL
ligands	NULL
and	NULL
agonists	NULL
for	NULL
PPARy	NULL
that	NULL
induce	NULL
PPAR-responsive	NULL
genes	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
PPARy	NULL
,	NULL
``	NULL
in	NULL
association	NULL
with	NULL
its	NULL
9-cis-retinoate-binding	NULL
RXR	NULL
partner	NULL
,	NULL
controls	NULL
metabolic	NULL
and	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
HL44513	NULL
,	NULL
HL	NULL
35217	NULL
,	NULL
HL34303	NULL
,	NULL
NS29632	NULL
,	NULL
and	NULL
HL	NULL
44525	NULL
,	NULL
the	NULL
Utah	NULL
Centers	NULL
of	NULL
Excellence	NULL
Program	NULL
,	NULL
and	NULL
the	NULL
Margolis	NULL
Foundation	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertise-ment	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

§	NULL
Current	NULL
address	NULL
:	NULL
Division	NULL
of	NULL
Clinical	NULL
Pharmacology	NULL
,	NULL
Vanderbilt	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Nashville	NULL
,	NULL
TN	NULL
87282	NULL
.	NULL

§§	NULL
H.	NULL
A.	NULL
and	NULL
Edna	NULL
Benning	NULL
Professor	NULL
of	NULL
Human	NULL
Molecular	NULL
Biology	NULL
.	NULL

T1	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
4180	NULL
EIHG	NULL
,	NULL
15	NULL
North	NULL
2030	NULL
East	NULL
,	NULL
University	NULL
of	NULL
Utah	NULL
,	NULL
Salt	NULL
Lake	NULL
City	NULL
,	NULL
UT	NULL
84112-5330	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
801-585-0716	NULL
;	NULL
Fax	NULL
:	NULL
801-585-0701	NULL
;	NULL
E-mail	NULL
:	NULL
tom.mcintyre	NULL
@	NULL
hmbg.utah.edu	NULL
.	NULL

*The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
PPAR	NULL
,	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
;	NULL
azPC	NULL
,	NULL
1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocho-line	NULL
;	NULL
TTA	NULL
,	NULL
tris	NULL
tosylamine	NULL
;	NULL
LDL	NULL
,	NULL
low	NULL
density	NULL
lipoprotein	NULL
;	NULL
oxLDL	NULL
,	NULL
oxidized	NULL
LDL	NULL
;	NULL
PPRE	NULL
,	NULL
PPAR-response	NULL
element	NULL
;	NULL
RXR	NULL
,	NULL
retinoid	NULL
X	NULL
receptor	NULL
;	NULL
HODE	NULL
,	NULL
hydroxyoctadecadienoic	NULL
acid	NULL
;	NULL
PG	NULL
,	NULL
prostaglandin	NULL
;	NULL
15-deoxy-PGJ	NULL
,	NULL
,	NULL
15-deoxy-A	NULL
'	NULL
``	NULL
``	NULL
*-prostaglandin	NULL
J	NULL
,	NULL
;	NULL
HPLC	NULL
,	NULL
high	NULL
pressure	NULL
liquid	NULL
chromatography	NULL
;	NULL
RP-HPLC	NULL
,	NULL
reversed	NULL
phase	NULL
HPLC	NULL
;	NULL
PBS	NULL
,	NULL
phosphate	NULL
This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
cellular	NULL
differentiation	NULL
genes	NULL
that	NULL
contain	NULL
variations	NULL
of	NULL
a	NULL
cognate	NULL
PPAR-response	NULL
element	NULL
(	NULL
1	NULL
)	NULL
.	NULL

PPARy	NULL
,	NULL
like	NULL
other	NULL
members	NULL
of	NULL
the	NULL
broad	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
family	NULL
,	NULL
undergoes	NULL
a	NULL
conformational	NULL
change	NULL
when	NULL
it	NULL
binds	NULL
specific	NULL
lipid	NULL
ligands	NULL
.	NULL

This	NULL
structural	NULL
reorganization	NULL
alters	NULL
its	NULL
associated	NULL
proteins	NULL
,	NULL
releasing	NULL
transcriptional	NULL
inhibitors	NULL
and	NULL
recruiting	NULL
transcriptional	NULL
co-activators	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
PPARy	NULL
function	NULL
is	NULL
therefore	NULL
controlled	NULL
by	NULL
lipid	NULL
ligand	NULL
binding	NULL
.	NULL

A	NULL
number	NULL
of	NULL
synthetic	NULL
ligands	NULL
for	NULL
PPAR	NULL
are	NULL
known	NULL
.	NULL

One	NULL
of	NULL
these	NULL
,	NULL
rosiglitazone	NULL
(	NULL
BRL49653	NULL
)	NULL
,	NULL
binds	NULL
with	NULL
high	NULL
affinity	NULL
and	NULL
is	NULL
widely	NULL
prescribed	NULL
as	NULL
an	NULL
insulin	NULL
sensitizer	NULL
in	NULL
type	NULL
II	NULL
diabetes	NULL
.	NULL

However	NULL
,	NULL
defining	NULL
relevant	NULL
biologic	NULL
ligands	NULL
has	NULL
been	NULL
problem-atic	NULL
.	NULL

Several	NULL
oxidatively	NULL
modified	NULL
fatty	NULL
acids	NULL
bind	NULL
and	NULL
activate	NULL
PPARy	NULL
,	NULL
including	NULL
15-deoxy-A	NULL
``	NULL
*	NULL
``	NULL
*-prostaglandin	NULL
J	NULL
;	NULL
(	NULL
15-deoxy-PGJ	NULL
,	NULL
;	NULL
)	NULL
,	NULL
other	NULL
arachidonate	NULL
metabolites	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
,	NULL
the	NULL
linoleate	NULL
derivatives	NULL
9-HODE	NULL
and	NULL
13-HODE	NULL
(	NULL
4	NULL
)	NULL
,	NULL
and	NULL
several	NULL
free	NULL
fatty	NULL
acids	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

However	NULL
,	NULL
none	NULL
of	NULL
these	NULL
are	NULL
particularly	NULL
potent	NULL
agonists	NULL
,	NULL
and	NULL
for	NULL
some	NULL
their	NULL
presence	NULL
at	NULL
concentrations	NULL
sufficient	NULL
to	NULL
activate	NULL
PPARy	NULL
can	NULL
be	NULL
questioned	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
oxygenated	NULL
fatty	NULL
acid	NULL
products	NULL
described	NULL
above	NULL
do	NULL
not	NULL
confer	NULL
much	NULL
advantage	NULL
in	NULL
potency	NULL
over	NULL
activation	NULL
by	NULL
free	NULL
arachidonate	NULL
(	NULL
7	NULL
)	NULL
where	NULL
a	NULL
concentration	NULL
of	NULL
several	NULL
micromolar	NULL
is	NULL
required	NULL
to	NULL
elicit	NULL
a	NULL
response	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
9-	NULL
and	NULL
13-HODEs	NULL
and	NULL
their	NULL
peroxides	NULL
found	NULL
in	NULL
oxidized	NULL
LDL	NULL
(	NULL
8	NULL
)	NULL
or	NULL
in	NULL
skin	NULL
exposed	NULL
to	NULL
the	NULL
tumor	NULL
promoter	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
9	NULL
)	NULL
are	NULL
esteri-fied	NULL
,	NULL
yet	NULL
only	NULL
the	NULL
free	NULL
forms	NULL
of	NULL
these	NULL
lipids	NULL
,	NULL
and	NULL
not	NULL
the	NULL
intact	NULL
phospholipids	NULL
from	NULL
these	NULL
sources	NULL
,	NULL
are	NULL
PPAR	NULL
ligands	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
the	NULL
PPARy	NULL
and	NULL
PPARa	NULL
agonist	NULL
15-deoxy-PGJ	NULL
,	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
accumulates	NULL
in	NULL
vivo	NULL
,	NULL
and	NULL
it	NULL
now	NULL
appears	NULL
that	NULL
little	NULL
15-deoxy-PGJ	NULL
;	NULL
is	NULL
actually	NULL
present	NULL
in	NULL
commercial	NULL
sources	NULL
of	NULL
this	NULL
reactive	NULL
and	NULL
unstable	NULL
lipid	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Oxidation	NULL
of	NULL
LDL	NULL
creates	NULL
unknown	NULL
PPARy	NULL
agonists	NULL
(	NULL
10	NULL
)	NULL
.	NULL

This	NULL
process	NULL
also	NULL
creates	NULL
PPARa	NULL
«	NULL
ligands	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
,	NULL
the	NULL
bulk	NULL
of	NULL
which	NULL
depend	NULL
on	NULL
liberation	NULL
by	NULL
phospholipase	NULL
A	NULL
;	NULL
to	NULL
free	NULL
fatty	NULL
acid	NULL
oxidation	NULL
products	NULL
(	NULL
13	NULL
)	NULL
.	NULL

PPARa	NULL
«	NULL
alters	NULL
lipid	NULL
metabolism	NULL
,	NULL
enhances	NULL
lipid	NULL
oxidation	NULL
,	NULL
and	NULL
often	NULL
dampens	NULL
inflammatory	NULL
events	NULL
and	NULL
signaling	NULL
pathways	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

PPARy	NULL
has	NULL
a	NULL
distinct	NULL
profile	NULL
of	NULL
activities	NULL
as	NULL
it	NULL
promotes	NULL
adipogenesis	NULL
through	NULL
differentiation	NULL
of	NULL
preadipocytes	NULL
,	NULL
and	NULL
it	NULL
may	NULL
have	NULL
a	NULL
complex	NULL
role	NULL
in	NULL
atherogenesis	NULL
(	NULL
1	NULL
,	NULL
16	NULL
)	NULL
.	NULL

In	NULL
part	NULL
,	NULL
its	NULL
pro-atherogenic	NULL
effects	NULL
may	NULL
occur	NULL
through	NULL
the	NULL
formation	NULL
of	NULL
foam	NULL
cells	NULL
by	NULL
stimulating	NULL
CD36	NULL
expression	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

CD36	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
scavenger	NULL
receptor	NULL
family	NULL
that	NULL
promotes	NULL
the	NULL
uptake	NULL
of	NULL
oxidized	NULL
LDL	NULL
,	NULL
driving	NULL
macrophages	NULL
to	NULL
a	NULL
lipid-surfeit	NULL
state	NULL
characterized	NULL
by	NULL
foamy	NULL
fatty	NULL
inclusions	NULL
.	NULL

Cells	NULL
in	NULL
atherosclerotic	NULL
lesions	NULL
express	NULL
PPARy	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
,	NULL
and	NULL
buffered	NULL
saline	NULL
;	NULL
PAF	NULL
,	NULL
platelet-activating	NULL
factor	NULL
;	NULL
PC	NULL
,	NULL
phosphatidylcho-line	NULL
;	NULL
FITC	NULL
,	NULL
fluorescein	NULL
isothiocyanate	NULL
.	NULL

16015	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
16016	NULL
CD36	NULL
is	NULL
induced	NULL
by	NULL
PPARy	NULL
agonists	NULL
present	NULL
in	NULL
oxidized	NULL
LDL	NULL
(	NULL
10	NULL
,	NULL
18	NULL
)	NULL
.	NULL

CD36	NULL
ligation	NULL
and	NULL
internalization	NULL
of	NULL
LDL	NULL
particles	NULL
oxidized	NULL
by	NULL
monocytes	NULL
is	NULL
blocked	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
oxidized	NULL
phospholipids	NULL
(	NULL
21	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
one	NULL
or	NULL
more	NULL
oxidized	NULL
phospholipids	NULL
is	NULL
a	NULL
CD36	NULL
ligand	NULL
responsible	NULL
for	NULL
the	NULL
internalization	NULL
of	NULL
oxLDL	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
a	NULL
complex	NULL
lipid	NULL
(	NULL
.e	NULL
.	NULL

a	NULL
phospholipid	NULL
)	NULL
formed	NULL
by	NULL
oxidative	NULL
attack	NULL
on	NULL
a	NULL
subclass	NULL
of	NULL
LDL	NULL
phospholipids	NULL
is	NULL
effectively	NULL
internalized	NULL
by	NULL
CD36	NULL
and	NULL
is	NULL
a	NULL
high	NULL
affinity	NULL
,	NULL
selective	NULL
PPARy	NULL
ligand	NULL
and	NULL
agonist	NULL
.	NULL

Alkyl	NULL
phosphatidylcholines	NULL
,	NULL
which	NULL
consist	NULL
of	NULL
a	NULL
small	NULL
portion	NULL
of	NULL
the	NULL
LDL	NULL
phosphatidylcholine	NULL
pool	NULL
(	NULL
22	NULL
)	NULL
,	NULL
are	NULL
the	NULL
sole	NULL
precursors	NULL
for	NULL
these	NULL
agonists	NULL
because	NULL
there	NULL
is	NULL
selectivity	NULL
for	NULL
the	NULL
bond	NULL
in	NULL
both	NULL
binding	NULL
and	NULL
PPRE	NULL
reporter	NULL
activation	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
certain	NULL
oxidized	NULL
alkyl	NULL
phospholipids	NULL
define	NULL
a	NULL
new	NULL
class	NULL
of	NULL
high	NULL
affinity	NULL
agonists	NULL
for	NULL
and	NULL
because	NULL
these	NULL
are	NULL
found	NULL
in	NULL
oxidized	NULL
LDL	NULL
,	NULL
they	NULL
may	NULL
contribute	NULL
to	NULL
its	NULL
biologic	NULL
effects	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Materials-PAF	NULL
was	NULL
from	NULL
Avanti	NULL
Polar	NULL
Lipids	NULL
;	NULL
lyso-PAF	NULL
(	NULL
1-O-hexa-	NULL
decyl-sn-glycero-3-phosphocholine	NULL
)	NULL
,	NULL
9-cis-retinoate	NULL
,	NULL
pirinixic	NULL
acid	NULL
(	NULL
WY14643	NULL
)	NULL
,	NULL
and	NULL
15-deoxy-PGJ	NULL
,	NULL
were	NULL
from	NULL
Biomol	NULL
;	NULL
Rhizopus	NULL
arrhizus	NULL
lipase	NULL
was	NULL
from	NULL
Roche	NULL
Molecular	NULL
Biochemicals	NULL
and	NULL
then	NULL
Sigma	NULL
;	NULL
[	NULL
®HJrosiglitazone	NULL
and	NULL
rosiglitazone	NULL
were	NULL
from	NULL
the	NULL
American	NULL
Radiola-beled	NULL
Chemicals	NULL
.	NULL

ECL	NULL
kits	NULL
were	NULL
from	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
;	NULL
the	NULL
SV40-B-galactosidase	NULL
reporter	NULL
was	NULL
from	NULL
Promega	NULL
(	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
;	NULL
the	NULL
CD36	NULL
reporter	NULL
constructs	NULL
with	NULL
(	NULL
-278	NULL
)	NULL
and	NULL
without	NULL
(	NULL
-261	NULL
)	NULL
its	NULL
PPRE	NULL
(	NULL
17	NULL
)	NULL
were	NULL
constructed	NULL
from	NULL
its	NULL
reported	NULL
sequence	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
forward	NULL
primers	NULL
(	NULL
for	NULL
CD86	NULL
-	NULL
``	NULL
``	NULL
)	NULL
were	NULL
5'-GCGACGCGTCTGGCCTCTGACTTA-CTTGG-3	NULL
'	NULL
or	NULL
(	NULL
CD86	NULL
-*	NULL
)	NULL
5-GCGACGCGTTTACTTGGATGGGAACTA-GCC-3	NULL
'	NULL
,	NULL
and	NULL
the	NULL
reverse	NULL
primer	NULL
was	NULL
TGCAGTCCTC-3	NULL
'	NULL
.	NULL

The	NULL
amplicon	NULL
was	NULL
inserted	NULL
into	NULL
pGL3b	NULL
at	NULL
the	NULL
M/ul	NULL
and	NULL
BegIl	NULL
sites	NULL
.	NULL

pGLSb	NULL
was	NULL
from	NULL
Promega	NULL
,	NULL
and	NULL
Probond	NULL
Ni	NULL
*	NULL
beads	NULL
were	NULL
from	NULL
Invitrogen	NULL
.	NULL

The	NULL
blocking	NULL
anti-CD86	NULL
antibody	NULL
185-1G2	NULL
,	NULL
without	NULL
azide	NULL
,	NULL
was	NULL
from	NULL
NeoMarkers	NULL
(	NULL
Fremont	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
the	NULL
FITC-conjugated	NULL
anti-CD36	NULL
antibody	NULL
CLB-IVC7	NULL
used	NULL
for	NULL
flow	NULL
analysis	NULL
was	NULL
from	NULL
Accurate	NULL
Chemicals	NULL
(	NULL
Westbury	NULL
,	NULL
NY	NULL
)	NULL
;	NULL
and	NULL
the	NULL
anti-ICAM-3	NULL
antibody	NULL
CAL8.10	NULL
(	NULL
BBA29	NULL
)	NULL
was	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
(	NULL
Minneapolis	NULL
MN	NULL
)	NULL
.	NULL

The	NULL
flippase	NULL
mimetic	NULL
I	NULL
(	NULL
24	NULL
)	NULL
tris	NULL
(	NULL
tosylaminoethyl	NULL
)	NULL
amine	NULL
(	NULL
TTA	NULL
)	NULL
was	NULL
synthesized	NULL
as	NULL
described	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Oxidation	NULL
and	NULL
Analysis	NULL
of	NULL
LDL	NULL
and	NULL
Synthetic	NULL
Phospholipids-LDL	NULL
was	NULL
oxidized	NULL
with	NULL
20	NULL
um	NULL
CuSO	NULL
,	NULL
at	NULL
37°C	NULL
overnight	NULL
,	NULL
and	NULL
oxidized	NULL
phospholipids	NULL
were	NULL
purified	NULL
by	NULL
RP-HPLC	NULL
(	NULL
26	NULL
)	NULL
.	NULL

A	NULL
portion	NULL
of	NULL
the	NULL
recovered	NULL
fractions	NULL
was	NULL
treated	NULL
with	NULL
phospholipase	NULL
A	NULL
,	NULL
as	NULL
before	NULL
(	NULL
27	NULL
)	NULL
,	NULL
exec-ept	NULL
that	NULL
the	NULL
enzyme	NULL
was	NULL
from	NULL
Sigma	NULL
.	NULL

The	NULL
lipid	NULL
azPC	NULL
was	NULL
synthesized	NULL
from	NULL
1-O-hexadecyl-sn-glycero-3-phosphocholine	NULL
(	NULL
hexadecyl	NULL
lyso-PC	NULL
;	NULL
after	NULL
mild	NULL
alkaline	NULL
hydrolysis	NULL
;	NULL
0.5	NULL
N	NULL
NaOH	NULL
in	NULL
methanol	NULL
;	NULL
4	NULL
h	NULL
;	NULL
24	NULL
°C	NULL
)	NULL
and	NULL
(	NULL
palmitoyl	NULL
azela-oy1-PC	NULL
)	NULL
was	NULL
synthesized	NULL
in	NULL
a	NULL
similar	NULL
fashion	NULL
from	NULL
palmitoyl	NULL
lyso-PC	NULL
.	NULL

After	NULL
neutralization	NULL
,	NULL
purified	NULL
lipid	NULL
(	NULL
2	NULL
mg	NULL
)	NULL
was	NULL
reacted	NULL
with	NULL
10	NULL
mg	NULL
of	NULL
azelaic	NULL
anhydride	NULL
(	NULL
University	NULL
of	NULL
Utah	NULL
Chemical	NULL
Synthesis	NULL
Facility	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
mg	NULL
of	NULL
4-	NULL
(	NULL
N	NULL
,	NULL
N-dimethylamino	NULL
)	NULL
pyridine	NULL
in	NULL
ine	NULL
(	NULL
4:1	NULL
)	NULL
for	NULL
36	NULL
h	NULL
before	NULL
purification	NULL
by	NULL
RP-HPLC	NULL
.	NULL

The	NULL
mass	NULL
of	NULL
each	NULL
synthetic	NULL
phospholipid	NULL
was	NULL
determined	NULL
by	NULL
phosphorus	NULL
analysis	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Mass	NULL
spectroscopy	NULL
of	NULL
lipid	NULL
oxidation	NULL
products	NULL
was	NULL
performed	NULL
as	NULL
before	NULL
(	NULL
27	NULL
)	NULL
.	NULL

[	NULL
PH	NULL
]	NULL
Hexadecy	NULL
]	NULL
azelaic	NULL
phosphatidylcholine	NULL
was	NULL
synthesized	NULL
from	NULL
(	NULL
PerkinElmer	NULL
Life	NULL
Scienc-es	NULL
)	NULL
and	NULL
HPLC-purified	NULL
in	NULL
a	NULL
similar	NULL
fashion	NULL
.	NULL

Cell	NULL
Preparation-Human	NULL
monocytes	NULL
were	NULL
isolated	NULL
by	NULL
counter-cur-rent	NULL
elutriation	NULL
(	NULL
29	NULL
)	NULL
and	NULL
resuspended	NULL
(	NULL
1	NULL
X	NULL
10°/ml	NULL
)	NULL
in	NULL
Hanks	NULL
'	NULL
balanced	NULL
salt	NULL
solution	NULL
with	NULL
0.5	NULL
%	NULL
human	NULL
serum	NULL
albumin	NULL
and	NULL
10	NULL
ug/ml	NULL
polymyxin	NULL
B.	NULL
Monocytes	NULL
were	NULL
added	NULL
to	NULL
plates	NULL
coated	NULL
with	NULL
10	NULL
ug/ml	NULL
CAL3.10	NULL
anti-ICAM-3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
80	NULL
)	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
ATCC	NULL
and	NULL
grown	NULL
as	NULL
suggested	NULL
.	NULL

Surface	NULL
expression	NULL
of	NULL
CD36	NULL
on	NULL
primary	NULL
human	NULL
monocytes	NULL
was	NULL
determined	NULL
by	NULL
allowing	NULL
elutriated	NULL
monocytes	NULL
to	NULL
adhere	NULL
to	NULL
anti-ICAMS-coated	NULL
wells	NULL
for	NULL
1	NULL
h	NULL
before	NULL
the	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
the	NULL
lipid	NULL
agonists	NULL
,	NULL
or	NULL
not	NULL
,	NULL
as	NULL
stated	NULL
in	NULL
the	NULL
figures	NULL
.	NULL

Some	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
a	NULL
suspended	NULL
state	NULL
by	NULL
gently	NULL
rocking	NULL
on	NULL
a	NULL
platform	NULL
rocker	NULL
in	NULL
polypropylene	NULL
tubes	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Adherent	NULL
cells	NULL
were	NULL
released	NULL
from	NULL
the	NULL
plate	NULL
by	NULL
gentle	NULL
agitation	NULL
and	NULL
scraping	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
PBS	NULL
containing	NULL
1	NULL
%	NULL
goat	NULL
serum	NULL
.	NULL

Recovered	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
FITC-labeled	NULL
anti-CD36	NULL
antibody	NULL
CLB-IVC	NULL
?	NULL

7	NULL
for	NULL
flow	NULL
analysis	NULL
by	NULL
the	NULL
University	NULL
of	NULL
Utah	NULL
flow	NULL
analysis	NULL
core	NULL
facility	NULL
.	NULL

Plasmids-The	NULL
acyl-CoA	NULL
oxidase-luciferase	NULL
plasmid	NULL
was	NULL
described	NULL
previously	NULL
(	NULL
81	NULL
)	NULL
.	NULL

Plasmids	NULL
were	NULL
transformed	NULL
into	NULL
TOP1OF	NULL
'	NULL
Escherichia	NULL
coli	NULL
strain	NULL
using	NULL
the	NULL
TA	NULL
cloning	NULL
kit	NULL
.	NULL

Plasmids	NULL
from	NULL
log	NULL
phase	NULL
cells	NULL
were	NULL
Oxidized	NULL
Phospholipids	NULL
Are	NULL
PPARy	NULL
Ligands	NULL
isolated	NULL
using	NULL
a	NULL
Bigger	NULL
Prep	NULL
kit	NULL
(	NULL
5	NULL
Prime	NULL
-	NULL
>	NULL
3	NULL
Prime	NULL
,	NULL
Inc.	NULL
,	NULL
Boulder	NULL
,	NULL
CO	NULL
)	NULL
,	NULL
and	NULL
purified	NULL
by	NULL
CsCl	NULL
gradients	NULL
.	NULL

The	NULL
His-tagged	NULL
PPARy	NULL
was	NULL
constructed	NULL
similarly	NULL
using	NULL
the	NULL
M13	NULL
primer	NULL
in	NULL
pCR2.1	NULL
that	NULL
contained	NULL
full-length	NULL
PPARy1	NULL
and	NULL
a	NULL
primer	NULL
(	NULL
5'-CTA	NULL
ATG	NULL
ATG	NULL
ATG	NULL
ATG	NULL
ATG	NULL
ATG	NULL
GTA	NULL
CAA	NULL
GTC	NULL
CTT	NULL
GTA	NULL
G-3	NULL
'	NULL
)	NULL
containing	NULL
the	NULL
His	NULL
,	NULL
tag	NULL
sequence	NULL
.	NULL

PPARy	NULL
and	NULL
PPARa	NULL
expression	NULL
plasmids	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
Beth	NULL
Meade	NULL
(	NULL
University	NULL
of	NULL
Utah	NULL
)	NULL
.	NULL

Inserts	NULL
in	NULL
all	NULL
plasmids	NULL
were	NULL
sequence-verified	NULL
by	NULL
the	NULL
University	NULL
of	NULL
Utah	NULL
sequencing	NULL
core	NULL
facility	NULL
.	NULL

Transfection	NULL
of	NULL
Cultured	NULL
Cells	NULL
and	NULL
Reporter	NULL
Assays-When	NULL
PPAR	NULL
expression	NULL
plasmids	NULL
were	NULL
co-transfected	NULL
with	NULL
a	NULL
reporter	NULL
construct	NULL
,	NULL
0.5	NULL
ug	NULL
of	NULL
the	NULL
relevant	NULL
plasmid	NULL
was	NULL
combined	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
pGL3-PPRE	NULL
and	NULL
0.1	NULL
ug	NULL
of	NULL
the	NULL
SV40-B-galactosidase	NULL
reporter	NULL
to	NULL
normalize	NULL
transfection	NULL
efficiencies	NULL
.	NULL

All	NULL
transfections	NULL
included	NULL
1-2	NULL
ug	NULL
of	NULL
total	NULL
plasmid	NULL
,	NULL
and	NULL
5-10	NULL
ul	NULL
of	NULL
LipofectAMINE	NULL
per	NULL
ml	NULL
of	NULL
Opti-MEM	NULL
.	NULL

Transfection	NULL
solution	NULL
was	NULL
added	NULL
to	NULL
CV-1	NULL
cells	NULL
overnight	NULL
and	NULL
then	NULL
removed	NULL
,	NULL
and	NULL
agonist	NULL
was	NULL
added	NULL
in	NULL
fresh	NULL
media	NULL
for	NULL
18-20	NULL
h.	NULL
[	NULL
°H|Rosiglitazone	NULL
displacement	NULL
from	NULL
PPARy	NULL
was	NULL
determined	NULL
with	NULL
a	NULL
carboxy	NULL
His	NULL
,	NULL
-tagged	NULL
molecule	NULL
.	NULL

Helia	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
pCR8.1-PPARy-His	NULL
,	NULL
or	NULL
pCR8.1	NULL
for	NULL
21	NULL
h	NULL
with	NULL
LipofectAMINE	NULL
and	NULL
then	NULL
grown	NULL
(	NULL
48	NULL
h	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
and	NULL
lysed	NULL
in	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
and	NULL
frozen	NULL
at	NULL
-70°C	NULL
until	NULL
used	NULL
.	NULL

Transfection	NULL
with	NULL
PPARy-His	NULL
,	NULL
was	NULL
assessed	NULL
by	NULL
immunoblotting	NULL
with	NULL
anti-His	NULL
,	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

Debris	NULL
was	NULL
removed	NULL
from	NULL
thawed	NULL
samples	NULL
,	NULL
and	NULL
200	NULL
ul	NULL
of	NULL
lysate	NULL
was	NULL
incubated	NULL
with	NULL
50	NULL
pl	NULL
of	NULL
Probond	NULL
beads	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
1	NULL
h	NULL
in	NULL
PBS	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
washed	NULL
once	NULL
by	NULL
centrifugation	NULL
before	NULL
[	NULL
*H	NULL
]	NULL
rosiglitazone	NULL
,	NULL
and	NULL
then	NULL
unlabeled	NULL
competitor	NULL
was	NULL
added	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
800	NULL
ul	NULL
of	NULL
PBS	NULL
.	NULL

Samples	NULL
were	NULL
incubated	NULL
with	NULL
shaking	NULL
for	NULL
3	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
before	NULL
washing	NULL
three	NULL
times	NULL
with	NULL
PBS	NULL
and	NULL
quantitating	NULL
retained	NULL
``	NULL
H.	NULL
Binding	NULL
of	NULL
phosphatidylcholine	NULL
to	NULL
PPARy	NULL
was	NULL
performed	NULL
in	NULL
a	NULL
similar	NULL
fashion	NULL
,	NULL
although	NULL
the	NULL
amount	NULL
of	NULL
protein	NULL
lysate	NULL
was	NULL
increased	NULL
to	NULL
account	NULL
for	NULL
its	NULL
lower	NULL
specific	NULL
radioactivity	NULL
.	NULL

Accumulation	NULL
of	NULL
[	NULL
°HJazPC	NULL
was	NULL
estimated	NULL
by	NULL
incubating	NULL
monolayers	NULL
with	NULL
carrier-free	NULL
[	NULL
°HJazPC	NULL
(	NULL
22.9	NULL
Ci/	NULL
mmol	NULL
)	NULL
for	NULL
30	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
lipids	NULL
specified	NULL
in	NULL
the	NULL
figure	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
uM	NULL
(	NULL
except	NULL
HPLC	NULL
fraction	NULL
6	NULL
from	NULL
oxLDL	NULL
that	NULL
was	NULL
used	NULL
at	NULL
a	NULL
concentration	NULL
that	NULL
maximally	NULL
induced	NULL
ACox	NULL
reporter	NULL
expression	NULL
since	NULL
there	NULL
was	NULL
insufficient	NULL
material	NULL
for	NULL
phosphorus	NULL
quan-titation	NULL
)	NULL
.	NULL

Some	NULL
cells	NULL
were	NULL
preincubated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
blocking	NULL
anti-CD86	NULL
antibody	NULL
185-1G2	NULL
or	NULL
an	NULL
irrelevant	NULL
IgG2Za	NULL
isotype-matched	NULL
control	NULL
monoclonal	NULL
antibody	NULL
.	NULL

RESULTS	NULL
Oxidized	NULL
Alkyl	NULL
Phosphatidylcholines	NULL
in	NULL
Oxidized	NULL
LDL	NULL
Stimulate	NULL
Luciferase	NULL
Expression	NULL
Under	NULL
the	NULL
Control	NULL
of	NULL
the	NULL
Acyl-CoA	NULL
Oxidase	NULL
PPRE-We	NULL
oxidized	NULL
human	NULL
LDL	NULL
,	NULL
extracted	NULL
the	NULL
lipids	NULL
,	NULL
and	NULL
separated	NULL
nonpolar	NULL
lipids	NULL
(	NULL
which	NULL
we	NULL
found	NULL
to	NULL
have	NULL
no	NULL
activity	NULL
in	NULL
this	NULL
assay	NULL
;	NULL
not	NULL
shown	NULL
)	NULL
from	NULL
the	NULL
polar	NULL
phospholipid	NULL
oxidation	NULL
products	NULL
.	NULL

We	NULL
separately	NULL
examined	NULL
these	NULL
polar	NULL
phos-pholipid-containing	NULL
fractions	NULL
as	NULL
agonists	NULL
using	NULL
CV-1	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
transiently	NULL
transfected	NULL
with	NULL
an	NULL
acyl-CoA	NULL
oxidase	NULL
PPRE-firefly	NULL
luciferase	NULL
reporter	NULL
construct	NULL
and	NULL
SV40-B-galactosidase	NULL
to	NULL
normalize	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

These	NULL
purified	NULL
polar	NULL
phospholipids	NULL
stimulated	NULL
luciferase	NULL
transcription	NULL
under	NULL
the	NULL
control	NULL
of	NULL
this	NULL
PPRE	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
and	NULL
this	NULL
activity	NULL
was	NULL
concentrated	NULL
in	NULL
RP-HPLC	NULL
fraction	NULL
6	NULL
.	NULL

We	NULL
found	NULL
this	NULL
material	NULL
to	NULL
be	NULL
as	NULL
effective	NULL
an	NULL
agonist	NULL
for	NULL
PPAR-induced	NULL
transcription	NULL
as	NULL
rosiglitazone	NULL
(	NULL
BRL49653	NULL
)	NULL
,	NULL
and	NULL
a	NULL
synthetic	NULL
oxidized	NULL
phospholipid	NULL
(	NULL
azPC	NULL
)	NULL
is	NULL
discussed	NULL
in	NULL
detail	NULL
below	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
shows	NULL
that	NULL
an	NULL
equivalent	NULL
fraction	NULL
from	NULL
the	NULL
same	NULL
batch	NULL
of	NULL
LDL	NULL
that	NULL
had	NULL
not	NULL
been	NULL
oxidized	NULL
contained	NULL
little	NULL
stimulatory	NULL
activity	NULL
.	NULL

Oxidation	NULL
of	NULL
LDL	NULL
creates	NULL
oxidized	NULL
phosphatidylcholines	NULL
that	NULL
are	NULL
potent	NULL
inflammatory	NULL
agents	NULL
because	NULL
they	NULL
structurally	NULL
resemble	NULL
PAF	NULL
and	NULL
activate	NULL
the	NULL
cloned	NULL
receptor	NULL
for	NULL
PAF	NULL
.	NULL

Oxidized	NULL
phospholipids	NULL
of	NULL
this	NULL
class	NULL
are	NULL
all	NULL
derived	NULL
from	NULL
the	NULL
small	NULL
pool	NULL
of	NULL
alkyl	NULL
phosphatidylcholines	NULL
in	NULL
LDL	NULL
(	NULL
22	NULL
)	NULL
that	NULL
are	NULL
resistant	NULL
to	NULL
phospholipase	NULL
A	NULL
;	NULL
,	NULL
digestion	NULL
(	NULL
27	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
oxidatively	NULL
generated	NULL
agonists	NULL
that	NULL
induce	NULL
transcription	NULL
from	NULL
a	NULL
PPRE	NULL
reporter	NULL
construct	NULL
also	NULL
fall	NULL
into	NULL
this	NULL
class	NULL
,	NULL
we	NULL
digested	NULL
the	NULL
fractions	NULL
isolated	NULL
by	NULL
HPLC	NULL
with	NULL
phospholipase	NULL
A	NULL
;	NULL
.	NULL

This	NULL
removes	NULL
the	NULL
oxidized	NULL
diacyl	NULL
phospholipids	NULL
,	NULL
derived	NULL
from	NULL
the	NULL
99.5	NULL
%	NULL
of	NULL
LDL	NULL
phospholipids	NULL
that	NULL
have	NULL
an	NULL
sm-1	NULL
ester	NULL
bond	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
phosphorus	NULL
analysis	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Phospholipase	NULL
A	NULL
;	NULL
digestion	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
fractions	NULL
isolated	NULL
from	NULL
oxidized	NULL
LDL	NULL
to	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Oxidized	NULL
Phospholipids	NULL
Are	NULL
PPARy	NULL
Ligands	NULL
450	NULL
;	NULL
[	NULL
]	NULL
Unoxidized	NULL
400	NULL
[	NULL
]	NULL
Oxidized	NULL
(	NULL
§	NULL
Ox	NULL
+	NULL
PLA	NULL
;	NULL
ACox-luciferase	NULL
Normalized	NULL
RLU	NULL
No	NULL
Pl	NULL
o	NULL
100	NULL
Buffer	NULL
Rosi	NULL
AzPC	NULL
HPLC	NULL
Fraction	NULL
Agonist	NULL
Fic	NULL
.	NULL

1.	NULL
oxLDL	NULL
contains	NULL
PPRE	NULL
agonists	NULL
that	NULL
are	NULL
resistant	NULL
to	NULL
phospholipase	NULL
A	NULL
,	NULL
digestion	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
luciferase	NULL
reporter	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
PPRE	NULL
from	NULL
acyl-CoA	NULL
oxidase	NULL
and	NULL
an	NULL
SV40-B-galactosidase	NULL
plasmid	NULL
to	NULL
normalize	NULL
transfection	NULL
efficiency	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
then	NULL
treated	NULL
for	NULL
18	NULL
h	NULL
with	NULL
buffer	NULL
,	NULL
1	NULL
uM	NULL
rosiglitazone	NULL
(	NULL
Rost	NULL
)	NULL
(	NULL
BRL49653	NULL
)	NULL
,	NULL
1	NULL
uM	NULL
of	NULL
the	NULL
synthetic	NULL
oxidized	NULL
phospholipid	NULL
azPC	NULL
,	NULL
or	NULL
equivalent	NULL
volumes	NULL
of	NULL
HPLC	NULL
fractions	NULL
of	NULL
lipids	NULL
extracted	NULL
from	NULL
native	NULL
or	NULL
oxidized	NULL
(	NULL
Ox	NULL
)	NULL
human	NULL
LDL	NULL
.	NULL

Each	NULL
reporter	NULL
was	NULL
then	NULL
assayed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experi-mental	NULL
Procedures	NULL
``	NULL
and	NULL
their	NULL
ratio	NULL
calculated	NULL
.	NULL

Polar	NULL
phospholipids	NULL
contained	NULL
in	NULL
Cu	NULL
``	NULL
-oxidized	NULL
LDL	NULL
were	NULL
purified	NULL
by	NULL
RP-HPLC	NULL
,	NULL
and	NULL
the	NULL
fractions	NULL
eluting	NULL
at	NULL
min	NULL
6-8	NULL
were	NULL
collected	NULL
;	NULL
the	NULL
solvent	NULL
was	NULL
removed	NULL
by	NULL
a	NULL
stream	NULL
of	NULL
N	NULL
;	NULL
;	NULL
and	NULL
the	NULL
remaining	NULL
lipids	NULL
were	NULL
resuspended	NULL
in	NULL
Hanks	NULL
'	NULL
balanced	NULL
salt	NULL
solution/A	NULL
by	NULL
a	NULL
brief	NULL
sonication	NULL
.	NULL

Polar	NULL
phospholipid	NULL
oxidation	NULL
products	NULL
with	NULL
PAF-like	NULL
activity	NULL
elute	NULL
at	NULL
min	NULL
5	NULL
and	NULL
6	NULL
and	NULL
PAF	NULL
elutes	NULL
in	NULL
fraction	NULL
7	NULL
(	NULL
27	NULL
)	NULL
in	NULL
this	NULL
system	NULL
.	NULL

An	NULL
aliquot	NULL
of	NULL
the	NULL
polar	NULL
phospholipids	NULL
isolated	NULL
from	NULL
oxidized	NULL
LDL	NULL
was	NULL
treated	NULL
with	NULL
phospholipase	NULL
A	NULL
;	NULL
and	NULL
re-extracted	NULL
prior	NULL
to	NULL
inclusion	NULL
in	NULL
the	NULL
assay	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
range	NULL
of	NULL
two	NULL
determinations	NULL
and	NULL
represent	NULL
results	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
.	NULL

16017	NULL
stimulate	NULL
luciferase	NULL
expression	NULL
from	NULL
the	NULL
PPRE-reporter	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
only	NULL
alkyl	NULL
phosphatidylcholine	NULL
oxidation	NULL
products	NULL
were	NULL
effective	NULL
agonists	NULL
in	NULL
this	NULL
assay	NULL
.	NULL

Azelaoyl	NULL
Phosphatidylcholine	NULL
Is	NULL
a	NULL
Prominent	NULL
Oxidation	NULL
Product	NULL
in	NULL
Oxidized	NULL
LDL-We	NULL
determined	NULL
which	NULL
alkyl	NULL
phosphatidylcholine	NULL
oxidation	NULL
products	NULL
were	NULL
present	NULL
in	NULL
oxidized	NULL
LDL	NULL
by	NULL
resolving	NULL
the	NULL
phospholipase	NULL
A	NULL
,	NULL
-treated	NULL
phospholipids	NULL
by	NULL
reversed	NULL
phase	NULL
HPLC	NULL
and	NULL
examining	NULL
these	NULL
by	NULL
electrospray	NULL
tandem	NULL
mass	NULL
spectroscopy	NULL
as	NULL
precursors	NULL
of	NULL
the	NULL
phosphocholine	NULL
ion	NULL
m/z	NULL
184	NULL
.	NULL

An	NULL
abundant	NULL
ion	NULL
in	NULL
the	NULL
HPLC	NULL
effluent	NULL
was	NULL
observed	NULL
at	NULL
m/z	NULL
652	NULL
(	NULL
Fig	NULL
.	NULL

20	NULL
)	NULL
,	NULL
potentially	NULL
corresponding	NULL
to	NULL
1-O-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine	NULL
(	NULL
azPC	NULL
)	NULL
.	NULL

This	NULL
component	NULL
was	NULL
maximal	NULL
in	NULL
RP-HPLC	NULL
fraction	NULL
6	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
inset	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
C	NULL
,	NULL
-PAF	NULL
analogs	NULL
were	NULL
most	NULL
abundant	NULL
in	NULL
fractions	NULL
7	NULL
and	NULL
8	NULL
,	NULL
as	NULL
reported	NULL
previously	NULL
(	NULL
27	NULL
)	NULL
.	NULL

A	NULL
structurally	NULL
unique	NULL
diagnostic	NULL
product	NULL
of	NULL
sm-2	NULL
©-carboxyl	NULL
glycerophosphocholine	NULL
lipids	NULL
is	NULL
the	NULL
collision-induced	NULL
rearrangement	NULL
of	NULL
a	NULL
methyl	NULL
group	NULL
and	NULL
decomposition	NULL
to	NULL
a	NULL
monomethyl	NULL
acid	NULL
and	NULL
dimethyl	NULL
lyso-PC	NULL
(	NULL
82	NULL
)	NULL
.	NULL

Proof	NULL
that	NULL
azPC	NULL
was	NULL
present	NULL
was	NULL
obtained	NULL
by	NULL
collision-induced	NULL
decomposition	NULL
of	NULL
the	NULL
corresponding	NULL
[	NULL
M	NULL
-	NULL
HJ~	NULL
of	NULL
m/z	NULL
650	NULL
(	NULL
Fig	NULL
.	NULL

2b	NULL
)	NULL
that	NULL
yielded	NULL
the	NULL
expected	NULL
product	NULL
ions	NULL
at	NULL
m/z	NULL
201	NULL
and	NULL
466	NULL
corresponding	NULL
to	NULL
monomethyl	NULL
azelaic	NULL
acid	NULL
and	NULL
the	NULL
dimethyl	NULL
lyso-PAF	NULL
adduct	NULL
resulting	NULL
from	NULL
the	NULL
loss	NULL
of	NULL
the	NULL
sm-2	NULL
methylazelaoyl	NULL
ketene	NULL
.	NULL

azPC	NULL
is	NULL
therefore	NULL
an	NULL
abundant	NULL
oxidation	NULL
product	NULL
of	NULL
LDL	NULL
alkyl	NULL
phosphatidylcholines	NULL
.	NULL

We	NULL
confirmed	NULL
this	NULL
deduction	NULL
by	NULL
synthesizing	NULL
azPC	NULL
and	NULL
finding	NULL
that	NULL
synthetic	NULL
azPC	NULL
produced	NULL
the	NULL
same	NULL
fragmentation	NULL
pattern	NULL
as	NULL
the	NULL
material	NULL
isolated	NULL
from	NULL
oxidized	NULL
LDL	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Synthetic	NULL
Hexadecyl	NULL
Azelaoyl	NULL
Phosphatidylcholine	NULL
Is	NULL
a	NULL
High	NULL
Affinity	NULL
Ligand	NULL
for	NULL
PPARy-We	NULL
experimentally	NULL
determined	NULL
a	NULL
Fraction	NULL
6	NULL
+V	NULL
100	NULL
e	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Identification	NULL
of	NULL
hexadecyl	NULL
azelaoyl	NULL
phosphatidyleholine	NULL
in	NULL
oxidized	NULL
LDL	NULL
.	NULL

a	NULL
,	NULL
electrospray	NULL
tandem	NULL
mass	NULL
spectroscopy	NULL
of	NULL
precursor-positive	NULL
ions	NULL
that	NULL
yield	NULL
m/z	NULL
184	NULL
ions	NULL
(	NULL
phosphocholine	NULL
cation	NULL
)	NULL
in	NULL
oxidized	NULL
LDL	NULL
.	NULL

LDL	NULL
was	NULL
oxi-dized	NULL
,	NULL
the	NULL
phospholipid	NULL
fraction	NULL
collected	NULL
by	NULL
aminopropyl	NULL
chromatography	NULL
,	NULL
and	NULL
treated	NULL
with	NULL
phospholipase	NULL
A	NULL
,	NULL
.	NULL

The	NULL
unhy-drolyzed	NULL
alkyl	NULL
polar	NULL
phospholipids	NULL
were	NULL
re-extracted	NULL
,	NULL
resolved	NULL
by	NULL
RP-HPLC	NULL
,	NULL
and	NULL
collected	NULL
as	NULL
they	NULL
eluted	NULL
from	NULL
the	NULL
column	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Mass	NULL
spectral	NULL
analysis	NULL
of	NULL
a	NULL
Relative	NULL
Abundance	NULL
portion	NULL
of	NULL
each	NULL
fraction	NULL
revealed	NULL
the	NULL
pop-	NULL
544.4	NULL
ulation	NULL
of	NULL
[	NULL
M	NULL
+	NULL
HJ*	NULL
ions	NULL
derived	NULL
from	NULL
phosphatidylcholine	NULL
or	NULL
sphingomyelin	NULL
generated	NULL
by	NULL
electrospray	NULL
ionization	NULL
included	NULL
m/z	NULL
652	NULL
,	NULL
the	NULL
expected	NULL
[	NULL
M	NULL
+	NULL
HJ~*	NULL
for	NULL
azPC	NULL
,	NULL
as	NULL
a	NULL
predominant	NULL
component	NULL
of	NULL
RP-HPLC	NULL
fraction	NULL
6	NULL
.	NULL

Inset	NULL
,	NULL
abundance	NULL
of	NULL
[	NULL
M	NULL
+	NULL
HJ~	NULL
ions	NULL
derived	NULL
from	NULL
azPC	NULL
(	NULL
m/z	NULL
500	NULL
652	NULL
)	NULL
and	NULL
C	NULL
,	NULL
-PAF	NULL
(	NULL
m/z	NULL
552	NULL
)	NULL
during	NULL
flow	NULL
injection	NULL
analysis	NULL
of	NULL
fractions	NULL
collected	NULL
during	NULL
RP-HPLC	NULL
separation	NULL
of	NULL
oxidized	NULL
LDL	NULL
phospholipids	NULL
.	NULL

b	NULL
,	NULL
product	NULL
ions	NULL
ob-	NULL
b	NULL
tained	NULL
following	NULL
collision-induced	NULL
decom-	NULL
position	NULL
of	NULL
the	NULL
corresponding	NULL
negative	NULL
ion	NULL
[	NULL
M	NULL
-	NULL
HJ~	NULL
at	NULL
m/z	NULL
650	NULL
revealed	NULL
the	NULL
diag-	NULL
nostic	NULL
carboxylate	NULL
anion	NULL
m/z	NULL
201	NULL
corre-	NULL
sponding	NULL
to	NULL
the	NULL
monomethyl	NULL
ester	NULL
of	NULL
aze-	NULL
laic	NULL
acid	NULL
and	NULL
the	NULL
dimethyl	NULL
lyso-PAF	NULL
anion	NULL
at	NULL
m/z	NULL
466	NULL
formed	NULL
by	NULL
loss	NULL
of	NULL
the	NULL
smn-2	NULL
substituent	NULL
as	NULL
a	NULL
ketene	NULL
.	NULL

100	NULL
~Ve	NULL
Relative	NULL
Abundance	NULL
544	NULL
MS/MS	NULL
m/z	NULL
650.4	NULL
-	NULL
ch	NULL
,	NULL
0	NULL
652	NULL
622	NULL
Fraction	NULL
:	NULL
_	NULL
6	NULL
7	NULL
8_	NULL
_9	NULL
_	NULL
10°	NULL
719	NULL
|	NULL
19,029	NULL
706	NULL
K	NULL
azPC	NULL
m/z	NULL
652.5	NULL
666	NULL
T	NULL
K	NULL
(	NULL
16,844	NULL
596	NULL
C4-PAF	NULL
m/z	NULL
552.4	NULL
783	NULL
Come	NULL
600	NULL
~	NULL
700	NULL
soo	NULL
_	NULL
_	NULL
900	NULL
201	NULL
azPC_	NULL
[	NULL
M-H	NULL
]	NULL
o	NULL
201	NULL
043/01	NULL
eso	NULL
I	NULL
CH3	NULL
0	NULL
P'CHS	NULL
15	NULL
+H	NULL
©	NULL
_	NULL
on	NULL
,	NULL
1425	NULL
16°	NULL
394	NULL
591	NULL
‘	NULL
311	NULL
466	NULL
‘	NULL
‘	NULL
:	NULL
HM	NULL
nh	NULL
atl	NULL
bar	NULL
sagen	NULL
foe	NULL
itioint	NULL
oll	NULL
‘	NULL
22	NULL
uae	NULL
.	NULL

il	NULL
.	NULL

ca	NULL
aul	NULL
100	NULL
200	NULL
300	NULL
400	NULL
500	NULL
600	NULL
m/z	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
16018	NULL
120	NULL
100	NULL
{	NULL
80	NULL
60	NULL
40	NULL
1	NULL
[	NULL
3HJazPC	NULL
bound	NULL
(	NULL
pmol	NULL
)	NULL
20	NULL
0	NULL
200	NULL
400	NULL
600	NULL
Lysate	NULL
Amount	NULL
(	NULL
jil	NULL
)	NULL
1400	NULL
1200	NULL
1000	NULL
800	NULL
600	NULL
400	NULL
Agonist	NULL
Bound	NULL
(	NULL
fMoles	NULL
)	NULL
200	NULL
/_ITI	NULL
'	NULL
I	NULL
'	NULL
I	NULL
'	NULL
I—	NULL
0	NULL
0.05	NULL
0.1	NULL
015	NULL
0.2	NULL
15	NULL
2.0	NULL
azPC	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
©	NULL
420	NULL
-	NULL
@	NULL
-	NULL
azPC	NULL
100	NULL
1	NULL
--	NULL
Rosi	NULL
80	NULL
40	NULL
{	NULL
Agonist	NULL
Bound	NULL
(	NULL
fMoles	NULL
)	NULL
20	NULL
T	NULL
T	NULL
0	NULL
0.5	NULL
1	NULL
1.5	NULL
2	NULL
Agonist	NULL
Added	NULL
(	NULL
BH	NULL
pMoles	NULL
)	NULL
Fic	NULL
.	NULL

3.	NULL
azPC	NULL
is	NULL
a	NULL
high	NULL
affinity	NULL
ligand	NULL
for	NULL
PPARy	NULL
.	NULL

a	NULL
,	NULL
[	NULL
*HJazPC	NULL
binds	NULL
to	NULL
immobilized	NULL
full-length	NULL
PPARy	NULL
.	NULL

Lysates	NULL
were	NULL
prepared	NULL
from	NULL
HeLa	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
plasmid	NULL
pCR3.1-PPARy-His	NULL
,	NULL
or	NULL
pCR3.1	NULL
,	NULL
and	NULL
the	NULL
ectopic	NULL
protein	NULL
from	NULL
the	NULL
stated	NULL
amount	NULL
of	NULL
lysate	NULL
was	NULL
immobilized	NULL
on	NULL
Ni*	NULL
beads	NULL
.	NULL

Charged	NULL
or	NULL
uncharged	NULL
beads	NULL
were	NULL
incubated	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
azPC	NULL
before	NULL
the	NULL
beads	NULL
were	NULL
recovered	NULL
and	NULL
washed	NULL
,	NULL
and	NULL
associated	NULL
radioactivity	NULL
was	NULL
quantitated	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

6	NULL
,	NULL
[	NULL
®HJazPC	NULL
binding	NULL
to	NULL
immobilized	NULL
PPAR	NULL
as	NULL
a	NULL
function	NULL
of	NULL
azPC	NULL
concentration	NULL
.	NULL

hPPARy	NULL
,	NULL
-His	NULL
,	NULL
immobilized	NULL
on	NULL
Ni*	NULL
beads	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
stated	NULL
concentration	NULL
of	NULL
azPC	NULL
before	NULL
bound	NULL
material	NULL
was	NULL
quantitated	NULL
as	NULL
above	NULL
.	NULL

The	NULL
range	NULL
of	NULL
duplicate	NULL
points	NULL
from	NULL
1	NULL
of	NULL
8	NULL
representative	NULL
experiments	NULL
is	NULL
presented	NULL
.	NULL

c	NULL
,	NULL
direct	NULL
comparison	NULL
of	NULL
[	NULL
°HJazPC	NULL
and	NULL
[	NULL
*HJ	NULL
]	NULL
ro-siglitazone	NULL
binding	NULL
at	NULL
low	NULL
concentrations	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
carrier-free	NULL
or	NULL
whose	NULL
concentrations	NULL
were	NULL
calculated	NULL
from	NULL
their	NULL
specific	NULL
radioactivity	NULL
,	NULL
retained	NULL
by	NULL
immobilized	NULL
PPARy	NULL
,	NULL
-His	NULL
,	NULL
was	NULL
determined	NULL
as	NULL
in	NULL
the	NULL
above	NULL
experiments	NULL
.	NULL

whether	NULL
a	NULL
complex	NULL
lipid	NULL
like	NULL
azPC	NULL
could	NULL
function	NULL
as	NULL
a	NULL
ligand	NULL
for	NULL
PPARy	NULL
.	NULL

We	NULL
synthesized	NULL
[	NULL
°HJhexadecyl	NULL
azelaoyl	NULL
phosphatidylcholine	NULL
(	NULL
[	NULL
°HJazPC	NULL
)	NULL
and	NULL
incubated	NULL
it	NULL
with	NULL
full-length	NULL
recombinant	NULL
human	NULL
PPARy	NULL
,	NULL
;	NULL
.	NULL

The	NULL
PPARy	NULL
in	NULL
transfected	NULL
Hela	NULL
cell	NULL
lysates	NULL
was	NULL
immobilized	NULL
on	NULL
Ni	NULL
*	NULL
beads	NULL
through	NULL
an	NULL
introduced	NULL
His	NULL
,	NULL
tag	NULL
,	NULL
so	NULL
tight	NULL
binding	NULL
could	NULL
be	NULL
assessed	NULL
after	NULL
collecting	NULL
and	NULL
washing	NULL
the	NULL
beads	NULL
.	NULL

We	NULL
found	NULL
(	NULL
Fig	NULL
.	NULL

30	NULL
)	NULL
that	NULL
[	NULL
°HJazPC	NULL
bound	NULL
to	NULL
PPARy	NULL
,	NULL
and	NULL
that	NULL
this	NULL
binding	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
concen-	NULL
Oxidized	NULL
Phospholipids	NULL
Are	NULL
PPARy	NULL
Ligands	NULL
tration	NULL
of	NULL
immobilized	NULL
hPPARy	NULL
;	NULL
,	NULL
.	NULL

We	NULL
next	NULL
varied	NULL
the	NULL
concentration	NULL
of	NULL
[	NULL
°HJazPC	NULL
to	NULL
establish	NULL
its	NULL
apparent	NULL
affinity	NULL
for	NULL
PPARy	NULL
under	NULL
these	NULL
conditions	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
[	NULL
®HJazPC	NULL
was	NULL
concentration-dependent	NULL
and	NULL
that	NULL
its	NULL
apparent	NULL
affinity	NULL
was	NULL
~40	NULL
nm	NULL
(	NULL
Fig	NULL
.	NULL

3b	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
also	NULL
found	NULL
that	NULL
different	NULL
lysates	NULL
provided	NULL
different	NULL
apparent	NULL
affinities	NULL
,	NULL
perhaps	NULL
reflecting	NULL
a	NULL
similar	NULL
wide	NULL
disparity	NULL
in	NULL
reported	NULL
apparent	NULL
affinities	NULL
for	NULL
rosigitazone	NULL
(	NULL
2	NULL
,	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
better	NULL
whether	NULL
azPC	NULL
bound	NULL
PPARy	NULL
as	NULL
effectively	NULL
as	NULL
rosigitazone	NULL
,	NULL
we	NULL
directly	NULL
compared	NULL
PHJazPC	NULL
binding	NULL
with	NULL
[	NULL
3H	NULL
]	NULL
rosig1itazone	NULL
binding	NULL
at	NULL
low	NULL
concentrations	NULL
and	NULL
found	NULL
(	NULL
Fig	NULL
.	NULL

3¢	NULL
)	NULL
that	NULL
[	NULL
°HJazPC	NULL
binding	NULL
precisely	NULL
mirrored	NULL
the	NULL
binding	NULL
of	NULL
[	NULL
°H	NULL
}	NULL
rosiglitazone	NULL
to	NULL
immobilized	NULL
PPARy1	NULL
.	NULL

Synthetic	NULL
azPC	NULL
Interacts	NULL
with	NULL
the	NULL
Ligand-binding	NULL
Pocket	NULL
of	NULL
PPARy-Rosiglitazone	NULL
co-crystallizes	NULL
with	NULL
the	NULL
ligand-binding	NULL
domain	NULL
of	NULL
PPARy	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
in	NULL
the	NULL
ligand-binding	NULL
pocket	NULL
,	NULL
so	NULL
displacement	NULL
of	NULL
[	NULL
°HJrosiglitazone	NULL
tests	NULL
binding	NULL
in	NULL
this	NULL
pocket	NULL
.	NULL

We	NULL
found	NULL
(	NULL
Fig	NULL
.	NULL

40	NULL
)	NULL
that	NULL
azPC	NULL
displaced	NULL
the	NULL
standard	NULL
ligand	NULL
[	NULL
PHJrosiglitazone	NULL
in	NULL
a	NULL
concentration-dependent	NULL
fashion	NULL
and	NULL
that	NULL
the	NULL
concentration	NULL
relationship	NULL
of	NULL
this	NULL
competition	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
of	NULL
unlabeled	NULL
rosiglitazone	NULL
.	NULL

azPC	NULL
bound	NULL
PPARy	NULL
only	NULL
through	NULL
this	NULL
ligand-binding	NULL
pocket	NULL
because	NULL
this	NULL
competition	NULL
with	NULL
rosiglitazone	NULL
was	NULL
complete	NULL
.	NULL

We	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
other	NULL
lipids	NULL
as	NULL
competitors	NULL
at	NULL
6.7	NULL
uM	NULL
where	NULL
azPC	NULL
and	NULL
rosiglitazone	NULL
competition	NULL
was	NULL
complete	NULL
and	NULL
found	NULL
(	NULL
Fig	NULL
.	NULL

45	NULL
)	NULL
that	NULL
PAF	NULL
and	NULL
15-deoxy-PGJ	NULL
;	NULL
,	NULL
could	NULL
only	NULL
displaced	NULL
about	NULL
a	NULL
third	NULL
of	NULL
the	NULL
[	NULL
PHJrosiglitazone	NULL
at	NULL
this	NULL
concentration	NULL
.	NULL

Free	NULL
azelaic	NULL
acid	NULL
,	NULL
like	NULL
arachidonate	NULL
,	NULL
was	NULL
an	NULL
ineffective	NULL
competitor	NULL
.	NULL

We	NULL
performed	NULL
the	NULL
converse	NULL
experiment	NULL
where	NULL
unlabeled	NULL
rosiglitazone	NULL
or	NULL
azPC	NULL
was	NULL
used	NULL
to	NULL
displace	NULL
[	NULL
PHJazPC	NULL
bound	NULL
to	NULL
immobilized	NULL
PPARy	NULL
.	NULL

We	NULL
found	NULL
(	NULL
Fig	NULL
.	NULL

4¢	NULL
)	NULL
that	NULL
unlabeled	NULL
rosiglitazone	NULL
displaced	NULL
nearly	NULL
all	NULL
of	NULL
the	NULL
[	NULL
PHJazPC	NULL
from	NULL
PPARy	NULL
as	NULL
its	NULL
concentration	NULL
was	NULL
increased	NULL
,	NULL
just	NULL
as	NULL
unlabeled	NULL
azPC	NULL
displaced	NULL
this	NULL
bound	NULL
[	NULL
°HJazPC	NULL
.	NULL

We	NULL
tested	NULL
other	NULL
lipids	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
displace	NULL
[	NULL
°HJazPC	NULL
and	NULL
found	NULL
(	NULL
Fig	NULL
.	NULL

4d	NULL
)	NULL
that	NULL
PAF	NULL
,	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
lyso-PAF	NULL
,	NULL
was	NULL
a	NULL
modest	NULL
competitor	NULL
,	NULL
but	NULL
that	NULL
9-HODE	NULL
or	NULL
13-HODE	NULL
were	NULL
unable	NULL
to	NULL
displace	NULL
bound	NULL
[	NULL
PHJazPC	NULL
.	NULL

We	NULL
tested	NULL
palmitoyl	NULL
azelaoyl-PC	NULL
,	NULL
the	NULL
diacyl	NULL
homolog	NULL
of	NULL
hexadecyl	NULL
azelaoyl	NULL
PC	NULL
,	NULL
as	NULL
a	NULL
PPARy	NULL
ligand	NULL
,	NULL
and	NULL
we	NULL
found	NULL
it	NULL
to	NULL
be	NULL
10-100-fold	NULL
less	NULL
potent	NULL
as	NULL
a	NULL
competitor	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

azPC	NULL
Is	NULL
a	NULL
Potent	NULL
Agonist	NULL
for	NULL
PPAR-responsive	NULL
Elements-azPC	NULL
was	NULL
a	NULL
ligand	NULL
for	NULL
PPARy	NULL
,	NULL
so	NULL
we	NULL
next	NULL
determined	NULL
whether	NULL
it	NULL
was	NULL
an	NULL
agonist	NULL
.	NULL

We	NULL
transfected	NULL
CV-1	NULL
cells	NULL
with	NULL
a	NULL
luciferase	NULL
reporter	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
PPRE	NULL
from	NULL
acyl-CoA	NULL
oxidase	NULL
,	NULL
along	NULL
with	NULL
SV40-§-galactosidase	NULL
as	NULL
a	NULL
transfection	NULL
control	NULL
,	NULL
and	NULL
then	NULL
treated	NULL
the	NULL
cells	NULL
with	NULL
rosiglitazone	NULL
,	NULL
synthetic	NULL
azPC	NULL
,	NULL
or	NULL
9-cis-retinoate	NULL
to	NULL
activate	NULL
RXR	NULL
.	NULL

Rosiglitazone	NULL
induced	NULL
a	NULL
3.4-fold	NULL
increase	NULL
in	NULL
reporter	NULL
expression	NULL
,	NULL
and	NULL
azPC	NULL
induced	NULL
a	NULL
3.9-fold	NULL
increase	NULL
(	NULL
Fig	NULL
.	NULL

5a	NULL
)	NULL
in	NULL
this	NULL
assay	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
presented	NULL
a	NULL
similar	NULL
result	NULL
where	NULL
azPC	NULL
induced	NULL
a	NULL
3.9-fold	NULL
increase	NULL
in	NULL
ACox	NULL
reporter	NULL
expression	NULL
.	NULL

Activation	NULL
of	NULL
just	NULL
the	NULL
RXR	NULL
subunit	NULL
with	NULL
9-cis-retinoate	NULL
,	NULL
which	NULL
can	NULL
act	NULL
as	NULL
a	NULL
phantom	NULL
ligand	NULL
(	NULL
37	NULL
)	NULL
,	NULL
was	NULL
not	NULL
as	NULL
effective	NULL
as	NULL
either	NULL
PPARy	NULL
ligand	NULL
in	NULL
stimulating	NULL
reporter	NULL
expression	NULL
.	NULL

We	NULL
compared	NULL
the	NULL
concentration-response	NULL
relationship	NULL
of	NULL
azPC	NULL
and	NULL
its	NULL
acyl	NULL
analog	NULL
with	NULL
rosiglitazone	NULL
as	NULL
PPARqy	NULL
agonists	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
ACox	NULL
reporter	NULL
and	NULL
SV40-B-galactosidase	NULL
for	NULL
normalization	NULL
,	NULL
and	NULL
we	NULL
then	NULL
treated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
azPC	NULL
,	NULL
diacyl	NULL
azPC	NULL
,	NULL
or	NULL
rosiglitazone	NULL
.	NULL

We	NULL
found	NULL
that	NULL
azPC	NULL
induced	NULL
a	NULL
concentration-dependent	NULL
increase	NULL
in	NULL
reporter	NULL
expression	NULL
starting	NULL
by	NULL
about	NULL
10~®	NULL
x	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
.	NULL

Half-maximal	NULL
activation	NULL
occurred	NULL
by	NULL
10	NULL
~	NULL
``	NULL
mM	NULL
,	NULL
and	NULL
maximal	NULL
expression	NULL
was	NULL
achieved	NULL
by	NULL
1	NULL
um	NULL
.	NULL

Rosiglitazone	NULL
also	NULL
induced	NULL
a	NULL
concentration-dependent	NULL
increase	NULL
,	NULL
and	NULL
this	NULL
relationship	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
of	NULL
azPC	NULL
.	NULL

We	NULL
also	NULL
examined	NULL
the	NULL
diacyl	NULL
homolog	NULL
of	NULL
azPC	NULL
,	NULL
1-palmitoyl-2-azelaoyl-sm-glycero-3-phosphocholine	NULL
,	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Oxidized	NULL
Phospholipids	NULL
Are	NULL
PPARy	NULL
Ligands	NULL
a	NULL
;	NULL
b	NULL
azPC	NULL
6	NULL
-	NULL
=	NULL
===	NULL
Rosi	NULL
n	NULL
0	NULL
5	NULL
4	NULL
po-o	NULL
/	NULL
”	NULL
\/\/\/\/	NULL
<	NULL
0_	NULL
[	NULL
BH	NULL
]	NULL
Rosi	NULL
Retained	NULL
(	NULL
dpm	NULL
x	NULL
10°	NULL
)	NULL
t	NULL
|	NULL
Relative	NULL
Rosi	NULL
Displacement	NULL
(	NULL
%	NULL
)	NULL
0	NULL
T	NULL
I	NULL
0	NULL
5	NULL
10	NULL
Competitor	NULL
(	NULL
x1	NULL
o-6	NULL
M	NULL
)	NULL
C	NULL
7	NULL
d	NULL
===	NULL
azPC	NULL
_L	NULL
6	NULL
===	NULL
«	NULL
Rosi	NULL
be	NULL
=	NULL
x	NULL
g	NULL
5	NULL
o.	NULL
I	NULL
3	NULL
4	NULL
(	NULL
-ic	NULL
©	NULL
tC	NULL
3	NULL
o	NULL
a.	NULL
N	NULL
&	NULL
<	NULL
2	NULL
Z	NULL
C	NULL
1	NULL
0	NULL
7	NULL
T	NULL
T	NULL
o	NULL
5	NULL
10	NULL
Competitor	NULL
(	NULL
x10°5	NULL
M	NULL
)	NULL
_s	NULL
o	NULL
a	NULL
at	NULL
I	NULL
[	NULL
BHJAzPC	NULL
Retained	NULL
(	NULL
dpm	NULL
x	NULL
103	NULL
)	NULL
16019	NULL
No	NULL
to	NULL
&	NULL
I	NULL
I	NULL
I	NULL
1	NULL
1	NULL
-x	NULL
1	NULL
Neg	NULL
azPC	NULL
Rosi	NULL
Lyso-	NULL
PAF	NULL
PAF	NULL
13-	NULL
9-HODE	NULL
HODE	NULL
Competitor	NULL
Agonist	NULL
Fic	NULL
.	NULL

4.	NULL
azPC	NULL
competes	NULL
for	NULL
rosiglitazone	NULL
(	NULL
Rosi	NULL
)	NULL
binding	NULL
in	NULL
the	NULL
PPAR	NULL
»	NULL
ligand-binding	NULL
pocket	NULL
.	NULL

a	NULL
,	NULL
azPC	NULL
displacement	NULL
of	NULL
[	NULL
*H	NULL
}	NULL
rosiglitazone	NULL
from	NULL
PPARy	NULL
.	NULL

(	NULL
0.33	NULL
nM	NULL
)	NULL
was	NULL
mixed	NULL
with	NULL
the	NULL
stated	NULL
concentration	NULL
of	NULL
unlabeled	NULL
rosiglitazone	NULL
or	NULL
azPC	NULL
before	NULL
the	NULL
amount	NULL
of	NULL
retained	NULL
by	NULL
immobilized	NULL
PPARy	NULL
was	NULL
determined	NULL
.	NULL

An	NULL
excess	NULL
(	NULL
18.6	NULL
uM	NULL
)	NULL
of	NULL
unlabeled	NULL
rosiglitazone	NULL
in	NULL
these	NULL
transfected	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
cell	NULL
lysates	NULL
reduced	NULL
binding	NULL
to	NULL
the	NULL
level	NULL
of	NULL
untransfected	NULL
cells	NULL
.	NULL

b	NULL
,	NULL
azPC	NULL
is	NULL
a	NULL
preferred	NULL
PPARy	NULL
ligand	NULL
.	NULL

Competitive	NULL
displacement	NULL
of	NULL
[	NULL
®HJrosiglitazone	NULL
from	NULL
Ni*-bound	NULL
PPARy	NULL
was	NULL
determined	NULL
with	NULL
an	NULL
excess	NULL
(	NULL
6.7	NULL
pM	NULL
)	NULL
of	NULL
the	NULL
stated	NULL
compound	NULL
.	NULL

c	NULL
,	NULL
azPC	NULL
binds	NULL
to	NULL
immobilized	NULL
PPARy	NULL
and	NULL
is	NULL
equally	NULL
displaced	NULL
by	NULL
rosiglitazone	NULL
or	NULL
unlabeled	NULL
azPC	NULL
.	NULL

The	NULL
stated	NULL
concentration	NULL
of	NULL
azPC	NULL
or	NULL
rosiglitazone	NULL
was	NULL
incubated	NULL
with	NULL
His	NULL
,	NULL
-PPARy	NULL
that	NULL
had	NULL
been	NULL
mixed	NULL
with	NULL
[	NULL
°HJazPC	NULL
before	NULL
the	NULL
amount	NULL
of	NULL
retained	NULL
radiolabel	NULL
was	NULL
determined	NULL
as	NULL
above	NULL
.	NULL

d	NULL
,	NULL
lipid	NULL
displacement	NULL
of	NULL
azPC	NULL
is	NULL
selective	NULL
.	NULL

Interference	NULL
of	NULL
[	NULL
°HJazPC	NULL
binding	NULL
to	NULL
PPARy	NULL
was	NULL
analyzed	NULL
as	NULL
in	NULL
b	NULL
with	NULL
an	NULL
excess	NULL
(	NULL
6.7	NULL
uM	NULL
)	NULL
of	NULL
the	NULL
stated	NULL
lipid	NULL
.	NULL

Neg	NULL
,	NULL
negative	NULL
.	NULL

as	NULL
an	NULL
agonist	NULL
;	NULL
we	NULL
found	NULL
that	NULL
it	NULL
was	NULL
about	NULL
100-fold	NULL
less	NULL
effective	NULL
than	NULL
azPC	NULL
and	NULL
only	NULL
began	NULL
to	NULL
elicit	NULL
an	NULL
effect	NULL
at	NULL
10	NULL
um	NULL
.	NULL

azPC	NULL
Is	NULL
a	NULL
Specific	NULL
PPARy	NULL
Agonist-We	NULL
determined	NULL
the	NULL
spec-ificity	NULL
of	NULL
azPC	NULL
as	NULL
a	NULL
PPARy	NULL
agonist	NULL
by	NULL
transfecting	NULL
CV-1	NULL
cells	NULL
with	NULL
PPARa	NULL
«	NULL
or	NULL
PPARy	NULL
expression	NULL
plasmids	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
ACox	NULL
reporter	NULL
and	NULL
an	NULL
SV40	NULL
-galactosidase	NULL
transfection	NULL
control	NULL
.	NULL

Rosiglitazone	NULL
induced	NULL
an	NULL
8-fold	NULL
increase	NULL
in	NULL
reporter	NULL
expression	NULL
in	NULL
this	NULL
experiment	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
in	NULL
untransfected	NULL
cells	NULL
that	NULL
rely	NULL
on	NULL
their	NULL
endogenous	NULL
PPARs	NULL
.	NULL

This	NULL
was	NULL
a	NULL
more	NULL
robust	NULL
response	NULL
than	NULL
the	NULL
5.3-fold	NULL
increase	NULL
induced	NULL
by	NULL
the	NULL
PPARa-selective	NULL
agonist	NULL
WY14643	NULL
or	NULL
the	NULL
5-fold	NULL
increase	NULL
induced	NULL
by	NULL
azPC	NULL
in	NULL
these	NULL
control	NULL
cells	NULL
.	NULL

When	NULL
PPARy	NULL
was	NULL
overexpressed	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
the	NULL
response	NULL
to	NULL
rosiglitazone	NULL
was	NULL
markedly	NULL
enhanced	NULL
(	NULL
a	NULL
25-fold	NULL
induction	NULL
)	NULL
,	NULL
as	NULL
was	NULL
the	NULL
response	NULL
to	NULL
azPC	NULL
(	NULL
an	NULL
18-fold	NULL
induction	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
overexpression	NULL
of	NULL
PPARa	NULL
failed	NULL
to	NULL
enhance	NULL
the	NULL
existing	NULL
response	NULL
to	NULL
either	NULL
azPC	NULL
or	NULL
rosiglitazone	NULL
.	NULL

The	NULL
ectopic	NULL
PPARa	NULL
was	NULL
functional	NULL
because	NULL
the	NULL
PPARa-selective	NULL
agonist	NULL
WY14643	NULL
enhanced	NULL
expression	NULL
in	NULL
cells	NULL
overexpressing	NULL
PPARa	NULL
and	NULL
not	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
PPARy	NULL
.	NULL

CD36	NULL
Is	NULL
Induced	NULL
by	NULL
azPC	NULL
through	NULL
Its	NULL
PPRE-We	NULL
determined	NULL
whether	NULL
endogenous	NULL
PPAR-regulated	NULL
genes	NULL
were	NULL
induced	NULL
by	NULL
azPC	NULL
,	NULL
and	NULL
for	NULL
this	NULL
we	NULL
chose	NULL
CD36	NULL
,	NULL
a	NULL
scavenger	NULL
receptor	NULL
that	NULL
binds	NULL
and	NULL
internalizes	NULL
oxidized	NULL
LDL	NULL
particles	NULL
.	NULL

Intriguingly	NULL
,	NULL
transcription	NULL
of	NULL
CD36	NULL
in	NULL
monocytes	NULL
is	NULL
stimulated	NULL
by	NULL
unknown	NULL
ligands	NULL
associated	NULL
with	NULL
oxidized	NULL
LDL	NULL
(	NULL
10	NULL
,	NULL
18	NULL
)	NULL
.	NULL

We	NULL
exposed	NULL
adherent	NULL
primary	NULL
human	NULL
monocytes	NULL
to	NULL
rosiglitazone	NULL
,	NULL
and	NULL
we	NULL
found	NULL
that	NULL
it	NULL
increased	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
CD36	NULL
as	NULL
expected	NULL
(	NULL
Fig	NULL
.	NULL

7a	NULL
)	NULL
.	NULL

There	NULL
was	NULL
an	NULL
equivalent	NULL
enhancement	NULL
of	NULL
CD36	NULL
surface	NULL
expression	NULL
when	NULL
monocytes	NULL
were	NULL
exposed	NULL
to	NULL
synthetic	NULL
azPC	NULL
.	NULL

Additionally	NULL
,	NULL
we	NULL
found	NULL
that	NULL
HPLC	NULL
fraction	NULL
6	NULL
of	NULL
oxidized	NULL
LDL	NULL
was	NULL
just	NULL
as	NULL
effective	NULL
as	NULL
azPC	NULL
and	NULL
rosiglitazone	NULL
in	NULL
enhancing	NULL
CD36	NULL
surface	NULL
expression	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
found	NULL
that	NULL
just	NULL
adhesion	NULL
and	NULL
spreading	NULL
of	NULL
the	NULL
monocytes	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
one	NULL
of	NULL
these	NULL
ligands	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
surface	NULL
CD36	NULL
expression	NULL
.	NULL

We	NULL
determined	NULL
whether	NULL
azPC	NULL
stimulated	NULL
CD36	NULL
transcription	NULL
by	NULL
using	NULL
CD36	NULL
promoter-reporter	NULL
constructs	NULL
that	NULL
either	NULL
contained	NULL
its	NULL
PPRE	NULL
at	NULL
position	NULL
-273	NULL
(	NULL
pCD36~*	NULL
``	NULL
°	NULL
)	NULL
or	NULL
lacked	NULL
this	NULL
element	NULL
(	NULL
pCD36	NULL
***	NULL
)	NULL
.	NULL

We	NULL
found	NULL
(	NULL
Fig	NULL
.	NULL

76	NULL
)	NULL
that	NULL
rosiglitazone	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
16020	NULL
a	NULL
3	NULL
800	NULL
ml	NULL
é	NULL
700	NULL
8	NULL
600-G	NULL
E	NULL
soo	NULL
o	NULL
Z	NULL
&	NULL
400	NULL
K3	NULL
§	NULL
soo	NULL
§	NULL
200	NULL
%	NULL
§	NULL
100	NULL
}	NULL
\	NULL
<	NULL
0	NULL
Buffer	NULL
Rosi	NULL
azPC	NULL
RA	NULL
b	NULL
5	NULL
Rosi	NULL
-=-	NULL
azPC	NULL
47	NULL
-~	NULL
.	NULL

acyl	NULL
azPC	NULL
Fold	NULL
induction	NULL
0	NULL
0	NULL
0.001	NULL
-	NULL
0.01	NULL
_	NULL
04	NULL
1	NULL
10	NULL
Agonist	NULL
(	NULL
uM	NULL
)	NULL
FiG	NULL
.	NULL

5.	NULL
a	NULL
,	NULL
azPC	NULL
fully	NULL
stimulates	NULL
reporter	NULL
expression	NULL
controlled	NULL
by	NULL
acyl-CoA	NULL
oxidase	NULL
PPRE	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
acyl-CoA-oxidase-PPRE-luciferase	NULL
(	NULL
ACox	NULL
)	NULL
reporter	NULL
construct	NULL
along	NULL
with	NULL
SV40-6-galactosidase	NULL
to	NULL
normalize	NULL
transfection	NULL
efficiency	NULL
.	NULL

After	NULL
1	NULL
h	NULL
of	NULL
recovery	NULL
,	NULL
these	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
18	NULL
h	NULL
with	NULL
200	NULL
nM	NULL
rosiglitazone	NULL
(	NULL
Rosi	NULL
)	NULL
,	NULL
200	NULL
nM	NULL
azPC	NULL
,	NULL
or	NULL
1	NULL
uM	NULL
O-cis-retinoate	NULL
(	NULL
RA	NULL
)	NULL
.	NULL

Firefly	NULL
luciferase	NULL
and	NULL
SV40-B-galactosidase	NULL
activities	NULL
in	NULL
the	NULL
cellular	NULL
lysates	NULL
were	NULL
determined	NULL
,	NULL
and	NULL
the	NULL
data	NULL
are	NULL
presented	NULL
as	NULL
this	NULL
normalized	NULL
ratio	NULL
.	NULL

b	NULL
,	NULL
azPC	NULL
stimulation	NULL
of	NULL
normalized	NULL
ACox-luciferase	NULL
expression	NULL
is	NULL
concentration-dependent	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
ACox-PPRE-luciferase	NULL
and	NULL
SV40-B-galactosidase	NULL
and	NULL
then	NULL
stimulated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
buffer	NULL
,	NULL
or	NULL
the	NULL
stated	NULL
amount	NULL
of	NULL
synthetic	NULL
azPC	NULL
,	NULL
diacyl	NULL
azPC	NULL
,	NULL
or	NULL
rosiglitazone	NULL
.	NULL

These	NULL
are	NULL
representative	NULL
results	NULL
from	NULL
one	NULL
of	NULL
two	NULL
experiments	NULL
.	NULL

I	NULL
+PPARy	NULL
35	NULL
[	NULL
_	NULL
]	NULL
Buffer	NULL
30	NULL
|	NULL
R	NULL
Rosi	NULL
[	NULL
Z	NULL
azPc	NULL
25	NULL
|C	NULL
wyi4e4s	NULL
20	NULL
15	NULL
10	NULL
5	NULL
0	NULL
PPRE	NULL
+PPARa	NULL
Normalized	NULL
Relative	NULL
Light	NULL
Units	NULL
(	NULL
x103	NULL
)	NULL
Fig	NULL
.	NULL

6.	NULL
azPC	NULL
is	NULL
a	NULL
selective	NULL
PPARy	NULL
agonist	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
acyl-CoA	NULL
oxidase-PPRE-luciferase	NULL
and	NULL
SV40-B-galactosidase	NULL
without	NULL
or	NULL
with	NULL
co-transfection	NULL
with	NULL
PPARa	NULL
or	NULL
PPARy	NULL
expression	NULL
plasmids	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
then	NULL
exposed	NULL
to	NULL
buffer	NULL
,	NULL
1	NULL
uM	NULL
rosiglitazone	NULL
(	NULL
Rosi	NULL
)	NULL
,	NULL
or	NULL
azPC	NULL
,	NULL
or	NULL
5	NULL
uM	NULL
WY14648	NULL
for	NULL
24	NULL
h	NULL
before	NULL
the	NULL
ratio	NULL
of	NULL
luciferase	NULL
to	NULL
B-galactosidase	NULL
was	NULL
determined	NULL
as	NULL
before	NULL
.	NULL

These	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
.	NULL

enhanced	NULL
pCD36	NULL
*	NULL
``	NULL
``	NULL
reporter	NULL
expression	NULL
in	NULL
CV-1	NULL
cells	NULL
through	NULL
endogenous	NULL
receptors	NULL
by	NULL
nearly	NULL
3-fold	NULL
and	NULL
that	NULL
exposure	NULL
to	NULL
azPC	NULL
produced	NULL
an	NULL
identical	NULL
response	NULL
.	NULL

This	NULL
induction	NULL
did	NULL
not	NULL
occur	NULL
when	NULL
we	NULL
used	NULL
pCD36	NULL
***	NULL
that	NULL
lacked	NULL
the	NULL
PPRE	NULL
.	NULL

We	NULL
next	NULL
co-transfected	NULL
these	NULL
cells	NULL
with	NULL
RXR	NULL
,	NULL
PPAR	NULL
«	NULL
,	NULL
or	NULL
both	NULL
RXR	NULL
and	NULL
PPARa	NULL
expression	NULL
plasmids	NULL
,	NULL
and	NULL
we	NULL
found	NULL
that	NULL
forced	NULL
expres-	NULL
Oxidized	NULL
Phospholipids	NULL
Are	NULL
PPARy	NULL
Ligands	NULL
sion	NULL
of	NULL
these	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
did	NULL
not	NULL
substantially	NULL
alter	NULL
these	NULL
results	NULL
.	NULL

However	NULL
,	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
co-transfected	NULL
with	NULL
PPARy	NULL
,	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
RXR	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
pCD36~*	NULL
``	NULL
``	NULL
°	NULL
by	NULL
rosiglitazone	NULL
was	NULL
markedly	NULL
enhanced	NULL
.	NULL

The	NULL
response	NULL
of	NULL
the	NULL
pCD36	NULL
**	NULL
reporter	NULL
plasmid	NULL
to	NULL
azPC	NULL
was	NULL
equally	NULL
augmented	NULL
by	NULL
overexpression	NULL
of	NULL
PPARy	NULL
.	NULL

This	NULL
augmentation	NULL
only	NULL
occurred	NULL
when	NULL
the	NULL
reporter	NULL
construct	NULL
contained	NULL
the	NULL
PPAR-responsive	NULL
element	NULL
,	NULL
so	NULL
activation	NULL
of	NULL
PPARy	NULL
,	NULL
and	NULL
not	NULL
PPARa	NULL
«	NULL
,	NULL
by	NULL
azPC	NULL
stimulates	NULL
CD36	NULL
expression	NULL
via	NULL
this	NULL
PPRE	NULL
.	NULL

CD36	NULL
Aids	NULL
in	NULL
the	NULL
Uptake	NULL
of	NULL
Extracellular	NULL
azPC-CD36	NULL
translocates	NULL
entire	NULL
oxidized	NULL
lipoprotein	NULL
particles	NULL
into	NULL
cells	NULL
,	NULL
apparently	NULL
by	NULL
binding	NULL
to	NULL
incorporated	NULL
oxidized	NULL
phospholipids	NULL
(	NULL
21	NULL
)	NULL
.	NULL

We	NULL
determined	NULL
whether	NULL
CD36	NULL
also	NULL
transports	NULL
extracellular	NULL
oxidized	NULL
phospholipids	NULL
not	NULL
incorporated	NULL
into	NULL
a	NULL
lipoprotein	NULL
particle	NULL
.	NULL

We	NULL
found	NULL
that	NULL
human	NULL
monocytes	NULL
accumulated	NULL
PHJazPC	NULL
and	NULL
that	NULL
this	NULL
accumulation	NULL
was	NULL
reduced	NULL
by	NULL
excess	NULL
unlabeled	NULL
azPC	NULL
or	NULL
the	NULL
polar	NULL
phospholipids	NULL
isolated	NULL
from	NULL
oxidized	NULL
LDL	NULL
(	NULL
Fig	NULL
.	NULL

8a	NULL
)	NULL
.	NULL

Excess	NULL
PAF	NULL
was	NULL
less	NULL
effective	NULL
in	NULL
blocking	NULL
PHJazPC	NULL
accumulation	NULL
and	NULL
inhibited	NULL
about	NULL
half	NULL
of	NULL
the	NULL
PHJazPC	NULL
accumulation	NULL
.	NULL

The	NULL
blocking	NULL
anti-CD36	NULL
antibody	NULL
185-1G2	NULL
also	NULL
blocked	NULL
half	NULL
of	NULL
the	NULL
specific	NULL
accumulation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
azPC	NULL
,	NULL
whereas	NULL
an	NULL
isotype-matched	NULL
control	NULL
monoclonal	NULL
antibody	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

We	NULL
next	NULL
transfected	NULL
CV-1	NULL
cells	NULL
with	NULL
the	NULL
ACox	NULL
PPRE	NULL
reporter	NULL
plasmid	NULL
and	NULL
then	NULL
treated	NULL
the	NULL
cells	NULL
with	NULL
the	NULL
blocking	NULL
anti-CD36	NULL
antibody	NULL
prior	NULL
to	NULL
exposing	NULL
these	NULL
cells	NULL
to	NULL
azPC	NULL
or	NULL
the	NULL
stimulatory	NULL
polar	NULL
phospholipids	NULL
purified	NULL
from	NULL
oxidized	NULL
LDL	NULL
.	NULL

We	NULL
found	NULL
(	NULL
Fig	NULL
.	NULL

8b	NULL
)	NULL
that	NULL
the	NULL
inhibitory	NULL
monoclonal	NULL
antibody	NULL
185-1G2	NULL
effectively	NULL
blocked	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
reporter	NULL
in	NULL
response	NULL
to	NULL
either	NULL
azPC	NULL
or	NULL
the	NULL
polar	NULL
phospholipids	NULL
isolated	NULL
from	NULL
oxidized	NULL
LDL	NULL
.	NULL

This	NULL
effect	NULL
did	NULL
not	NULL
extend	NULL
to	NULL
all	NULL
lipids	NULL
as	NULL
luciferase	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
rosiglitazone	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
the	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Extracellular	NULL
azPC	NULL
Has	NULL
Ready	NULL
Access	NULL
to	NULL
Intracellular	NULL
PPARy-Our	NULL
results	NULL
suggest	NULL
that	NULL
azPC	NULL
is	NULL
a	NULL
direct	NULL
agonist	NULL
for	NULL
PPARy	NULL
,	NULL
but	NULL
it	NULL
might	NULL
be	NULL
argued	NULL
that	NULL
azPC	NULL
activates	NULL
a	NULL
surface	NULL
receptor	NULL
whose	NULL
signal	NULL
induces	NULL
the	NULL
synthesis	NULL
of	NULL
the	NULL
true	NULL
intracellular	NULL
ligand	NULL
for	NULL
this	NULL
nuclear	NULL
receptor	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
enhancing	NULL
intracellular	NULL
access	NULL
of	NULL
azPC	NULL
should	NULL
have	NULL
no	NULL
effect	NULL
on	NULL
reporter	NULL
induction	NULL
.	NULL

We	NULL
tested	NULL
this	NULL
postulate	NULL
with	NULL
the	NULL
small	NULL
molecule	NULL
flippase	NULL
mimetic	NULL
TTA	NULL
(	NULL
Fig	NULL
.	NULL

90	NULL
)	NULL
that	NULL
facilitates	NULL
anionic	NULL
phospholipid	NULL
flip-flop	NULL
(	NULL
24	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
TTA	NULL
had	NULL
no	NULL
effect	NULL
of	NULL
its	NULL
own	NULL
on	NULL
ACox	NULL
reporter	NULL
expression	NULL
in	NULL
CV-1	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
but	NULL
that	NULL
it	NULL
doubled	NULL
the	NULL
1.7-fold	NULL
induction	NULL
of	NULL
the	NULL
acyl-CoA	NULL
oxidase	NULL
reporter	NULL
induced	NULL
by	NULL
azPC	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

9b	NULL
)	NULL
.	NULL

This	NULL
enhancement	NULL
in	NULL
azPC	NULL
activity	NULL
by	NULL
TTA	NULL
was	NULL
concentration-dependent	NULL
with	NULL
little	NULL
sign	NULL
of	NULL
toxicity	NULL
up	NULL
to	NULL
37	NULL
uM	NULL
,	NULL
the	NULL
concentration	NULL
used	NULL
to	NULL
study	NULL
vesicular	NULL
transport	NULL
(	NULL
24	NULL
)	NULL
.	NULL

This	NULL
cationic	NULL
lipid	NULL
also	NULL
doubled	NULL
reporter	NULL
expression	NULL
when	NULL
the	NULL
extracellular	NULL
agonist	NULL
was	NULL
an	NULL
intact	NULL
oxidized	NULL
LDL	NULL
particle	NULL
(	NULL
Fig	NULL
.	NULL

9¢	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
can	NULL
exchange	NULL
agonists	NULL
from	NULL
these	NULL
particles	NULL
as	NULL
well	NULL
.	NULL

This	NULL
is	NULL
not	NULL
the	NULL
anticipated	NULL
result	NULL
if	NULL
gene	NULL
induction	NULL
depended	NULL
on	NULL
signaling	NULL
from	NULL
an	NULL
externally	NULL
disposed	NULL
plasma	NULL
membrane	NULL
receptor	NULL
for	NULL
azPC	NULL
.	NULL

We	NULL
conclude	NULL
from	NULL
this	NULL
,	NULL
first	NULL
that	NULL
the	NULL
flippase	NULL
mimetic	NULL
aids	NULL
azPC	NULL
penetration	NULL
into	NULL
cells	NULL
and	NULL
thereby	NULL
enhances	NULL
transcription	NULL
by	NULL
nuclear	NULL
PPARy	NULL
.	NULL

Second	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
because	NULL
the	NULL
enhancement	NULL
was	NULL
quite	NULL
modest	NULL
that	NULL
azPC	NULL
transport	NULL
already	NULL
occurs	NULL
at	NULL
a	NULL
rate	NULL
that	NULL
supplies	NULL
near-maximal	NULL
amounts	NULL
of	NULL
extracellular	NULL
azPC	NULL
,	NULL
or	NULL
oxidized	NULL
ligands	NULL
in	NULL
oxidized	NULL
LDL	NULL
particles	NULL
,	NULL
to	NULL
intra-	NULL
cellular	NULL
PPARy	NULL
.	NULL

DISCUSSION	NULL
Our	NULL
findings	NULL
show	NULL
that	NULL
oxidatively	NULL
modified	NULL
phosphatidylcholines	NULL
from	NULL
oxidized	NULL
LDL	NULL
are	NULL
high	NULL
affinity	NULL
ligands	NULL
and	NULL
agonists	NULL
for	NULL
PPARy	NULL
.	NULL

We	NULL
find	NULL
that	NULL
there	NULL
is	NULL
a	NULL
distinct	NULL
selectivity	NULL
for	NULL
an	NULL
sn-1	NULL
ether	NULL
bond	NULL
in	NULL
both	NULL
binding	NULL
to	NULL
PPAR~y	NULL
and	NULL
its	NULL
activation	NULL
by	NULL
oxidized	NULL
phospholipids	NULL
.	NULL

The	NULL
selective	NULL
recognition	NULL
of	NULL
the	NULL
sn-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Oxidized	NULL
Phospholipids	NULL
Are	NULL
PPARy	NULL
Ligands	NULL
a	NULL
120	NULL
16021	NULL
Counts	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

CD36	NULL
is	NULL
induced	NULL
by	NULL
azPC	NULL
through	NULL
its	NULL
PPRE	NULL
.	NULL

a	NULL
,	NULL
azPC	NULL
enhances	NULL
CD36	NULL
surface	NULL
expression	NULL
in	NULL
primary	NULL
human	NULL
monocytes	NULL
.	NULL

Monocytes	NULL
freshly	NULL
isolated	NULL
by	NULL
elutriation	NULL
were	NULL
allowed	NULL
to	NULL
ad	NULL
120	NULL
Unactivated	NULL
azPC	NULL
Counts	NULL
here	NULL
to	NULL
anti-ICAM8-coated	NULL
wells	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
buffer	NULL
,	NULL
1	NULL
uM	NULL
azPC	NULL
,	NULL
rosiglitazone	NULL
(	NULL
Rosi	NULL
)	NULL
,	NULL
or	NULL
with	NULL
fraction	NULL
6	NULL
of	NULL
HPLC-purified	NULL
polar	NULL
phospholipids	NULL
derived	NULL
from	NULL
120	NULL
C	NULL
>	NULL
:	NULL
u	NULL
0	NULL
-	NULL
103	NULL
10	NULL
``	NULL
2	NULL
103	NULL
10	NULL
``	NULL
10	NULL
FL-1	NULL
Height	NULL
102	NULL
FL-1	NULL
Height	NULL
oxidized	NULL
LDL	NULL
.	NULL

After	NULL
overnight	NULL
incubation	NULL
,	NULL
these	NULL
cells	NULL
were	NULL
released	NULL
from	NULL
the	NULL
plate	NULL
100	NULL
4	NULL
and	NULL
stained	NULL
with	NULL
FITC-labeled	NULL
anti-CD36	NULL
antibody	NULL
CLB-IVC7	NULL
.	NULL

The	NULL
upper	NULL
left	NULL
panel	NULL
shows	NULL
that	NULL
adhesion	NULL
alone	NULL
was	NULL
not	NULL
stimulatory	NULL
as	NULL
CD36	NULL
expression	NULL
by	NULL
unactivated	NULL
cells	NULL
held	NULL
in	NULL
suspension	NULL
was	NULL
the	NULL
40	NULL
1	NULL
same	NULL
as	NULL
those	NULL
allowed	NULL
to	NULL
adhere	NULL
to	NULL
anti-ICAMS-coated	NULL
surfaces	NULL
.	NULL

b	NULL
,	NULL
azPC	NULL
stimulates	NULL
CD36	NULL
transcription	NULL
through	NULL
a	NULL
PPRE	NULL
o	NULL
3	NULL
80	NULL
1	NULL
60	NULL
4	NULL
Counts	NULL
Rosi	NULL
OxLDL	NULL
Fxn	NULL
6	NULL
Counts	NULL
Agonist	NULL
4	NULL
Agonist	NULL
idl	NULL
and	NULL
PPARy	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
CD36	NULL
promoter-luciferase	NULL
reporter	NULL
that	NULL
contained	NULL
its	NULL
PPRE	NULL
(	NULL
CD36~*'°	NULL
)	NULL
or	NULL
one	NULL
that	NULL
did	NULL
not	NULL
(	NULL
CD36-	NULL
``	NULL
°	NULL
``	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
co-transfected	NULL
with	NULL
SV40-B-galactosidase	NULL
,	NULL
b	NULL
aa	NULL
o	NULL
10	NULL
``	NULL
102	NULL
103	NULL
10	NULL
``	NULL
102	NULL
103	NULL
FL1	NULL
Height	NULL
FL-1	NULL
Height	NULL
and	NULL
some	NULL
cells	NULL
were	NULL
additionally	NULL
transfected	NULL
with	NULL
expression	NULL
plasmids	NULL
encoding	NULL
RXRa	NULL
,	NULL
PPARa	NULL
,	NULL
or	NULL
PPARy	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
treated	NULL
for	NULL
16	NULL
h	NULL
with	NULL
1	NULL
uM	NULL
rosiglitazone	NULL
or	NULL
azPC	NULL
before	NULL
the	NULL
ratio	NULL
of	NULL
luciferase	NULL
to	NULL
B-galactosidase	NULL
was	NULL
determined	NULL
and	NULL
normalized	NULL
to	NULL
buffer-treated	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
a	NULL
separate	NULL
experiment	NULL
.	NULL

Normalized	NULL
Fold	NULL
Increase	NULL
6	NULL
-	NULL
mn	NULL
@	NULL
a	NULL
a	NULL
o	NULL
~	NULL
o	NULL
w	NULL
ether	NULL
bond	NULL
means	NULL
that	NULL
the	NULL
LDL	NULL
precursors	NULL
of	NULL
these	NULL
high	NULL
affinity	NULL
ligands	NULL
are	NULL
derived	NULL
from	NULL
the	NULL
half	NULL
percent	NULL
or	NULL
so	NULL
of	NULL
alkyl	NULL
phosphatidylcholines	NULL
in	NULL
the	NULL
pool	NULL
of	NULL
LDL	NULL
phosphatidylcholine	NULL
(	NULL
22	NULL
)	NULL
.	NULL

One	NULL
prominent	NULL
oxidation	NULL
product	NULL
of	NULL
this	NULL
subclass	NULL
was	NULL
as	NULL
potent	NULL
as	NULL
the	NULL
synthetic	NULL
high	NULL
affinity	NULL
ligand	NULL
rosiglitazone	NULL
.	NULL

PPARy	NULL
is	NULL
a	NULL
ligand-dependent	NULL
transcriptional	NULL
activator	NULL
where	NULL
the	NULL
known	NULL
ligands	NULL
are	NULL
lipids	NULL
with	NULL
a	NULL
remarkably	NULL
wide	NULL
range	NULL
of	NULL
structures	NULL
.	NULL

Crystallography	NULL
reveals	NULL
a	NULL
large	NULL
hydropho-bic	NULL
ligand	NULL
cavity	NULL
that	NULL
is	NULL
only	NULL
25-40	NULL
%	NULL
occupied	NULL
by	NULL
rosiglitazone	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
a	NULL
variety	NULL
of	NULL
structures	NULL
might	NULL
be	NULL
able	NULL
to	NULL
be	NULL
accommodated	NULL
by	NULL
this	NULL
pocket	NULL
.	NULL

azPC	NULL
bound	NULL
PPARy	NULL
in	NULL
a	NULL
way	NULL
that	NULL
was	NULL
saturable	NULL
and	NULL
was	NULL
completely	NULL
displaced	NULL
by	NULL
rosiglitazone	NULL
.	NULL

This	NULL
latter	NULL
attribute	NULL
strongly	NULL
suggests	NULL
that	NULL
azPC	NULL
binds	NULL
in	NULL
the	NULL
ligand-binding	NULL
pocket	NULL
.	NULL

We	NULL
did	NULL
not	NULL
established	NULL
the	NULL
K	NULL
,	NULL
,	NULL
for	NULL
azPC	NULL
through	NULL
a	NULL
Scatchard	NULL
analysis	NULL
,	NULL
because	NULL
we	NULL
do	NULL
not	NULL
have	NULL
sufficient	NULL
immobilized	NULL
protein	NULL
for	NULL
quantitation	NULL
,	NULL
but	NULL
rather	NULL
have	NULL
established	NULL
its	NULL
apparent	NULL
binding	NULL
constant	NULL
.	NULL

The	NULL
value	NULL
we	NULL
obtained	NULL
for	NULL
an	NULL
apparent	NULL
affinity	NULL
of	NULL
azPC	NULL
for	NULL
PPARy	NULL
was	NULL
around	NULL
40	NULL
nM	NULL
,	NULL
but	NULL
we	NULL
also	NULL
found	NULL
variation	NULL
in	NULL
this	NULL
number	NULL
using	NULL
lysates	NULL
from	NULL
other	NULL
transfections	NULL
.	NULL

More	NULL
relevant	NULL
was	NULL
our	NULL
observation	NULL
that	NULL
in	NULL
a	NULL
direct	NULL
comparison	NULL
there	NULL
was	NULL
no	NULL
discernible	NULL
difference	NULL
between	NULL
[	NULL
3H	NULL
]	NULL
rosiglitazone	NULL
and	NULL
PHJazPC	NULL
binding	NULL
.	NULL

The	NULL
affinity	NULL
of	NULL
rosiglitazone	NULL
itself	NULL
for	NULL
PPARy	NULL
is	NULL
subject	NULL
to	NULL
variability	NULL
in	NULL
the	NULL
literature	NULL
ranging	NULL
from	NULL
40	NULL
to	NULL
60	NULL
nM	NULL
for	NULL
the	NULL
displacement	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
SB-236636	NULL
(	NULL
88	NULL
)	NULL
to	NULL
200	NULL
nx	NULL
for	NULL
the	NULL
displacement	NULL
of	NULL
[	NULL
3H	NULL
]	NULL
rosig1itazone	NULL
(	NULL
39	NULL
)	NULL
.	NULL

These	NULL
competitive	NULL
displacement	NULL
values	NULL
span	NULL
the	NULL
range	NULL
of	NULL
values	NULL
reported	NULL
for	NULL
the	NULL
actual	NULL
binding	NULL
constant	NULL
for	NULL
rosiglitazone	NULL
to	NULL
PPARy	NULL
,	NULL
where	NULL
the	NULL
K	NULL
,	NULL
ranges	NULL
from	NULL
40	NULL
(	NULL
83	NULL
)	NULL
to	NULL
100	NULL
(	NULL
84	NULL
)	NULL
to	NULL
325	NULL
nm	NULL
(	NULL
2	NULL
)	NULL
.	NULL

|	NULL
C	NULL
Rosi	NULL
CD36.273	NULL
WLFLJEJELHQ	NULL
I	NULL
azPC	NULL
CD36.273	NULL
®	NULL
Rosi	NULL
CD36.251	NULL
C	NULL
azPC	NULL
CD36.251	NULL
None	NULL
RXR	NULL
PPARG	NULL
:	NULL
RXR/	NULL
PPARYy	NULL
RXR/	NULL
Agonist	NULL
PPARa	NULL
PPARy	NULL
azPC	NULL
binding	NULL
to	NULL
PPARy	NULL
was	NULL
a	NULL
property	NULL
of	NULL
the	NULL
whole	NULL
anionic	NULL
phospholipid	NULL
structure	NULL
,	NULL
because	NULL
free	NULL
and	NULL
unesterified	NULL
azelaic	NULL
acid	NULL
did	NULL
not	NULL
compete	NULL
for	NULL
rosiglitazone	NULL
binding	NULL
.	NULL

However	NULL
,	NULL
not	NULL
all	NULL
polar	NULL
alkyl	NULL
phosphatidylcholines	NULL
interact	NULL
well	NULL
with	NULL
PPARy	NULL
because	NULL
PAF	NULL
was	NULL
a	NULL
poor	NULL
ligand	NULL
that	NULL
failed	NULL
to	NULL
induce	NULL
PPRE	NULL
reporter	NULL
expression	NULL
.	NULL

Nevertheless	NULL
the	NULL
sm-1	NULL
ether	NULL
bond	NULL
is	NULL
an	NULL
important	NULL
structural	NULL
determinant	NULL
because	NULL
the	NULL
diacyl	NULL
homolog	NULL
of	NULL
azPC	NULL
was	NULL
a	NULL
poor	NULL
ligand	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
an	NULL
even	NULL
less	NULL
effective	NULL
agonist	NULL
that	NULL
only	NULL
began	NULL
to	NULL
induce	NULL
PPRE	NULL
reporter	NULL
function	NULL
by	NULL
10	NULL
uM	NULL
.	NULL

This	NULL
selectivity	NULL
for	NULL
the	NULL
sm-1	NULL
ether	NULL
bond	NULL
is	NULL
the	NULL
basis	NULL
for	NULL
our	NULL
observation	NULL
that	NULL
phospholipase	NULL
A	NULL
,	NULL
treatment	NULL
of	NULL
the	NULL
mixed	NULL
oxidized	NULL
phospholipid	NULL
products	NULL
generated	NULL
by	NULL
LDL	NULL
oxidation	NULL
did	NULL
not	NULL
detectably	NULL
reduce	NULL
PPRE	NULL
reporter	NULL
activity	NULL
.	NULL

The	NULL
diacyl	NULL
azPC	NULL
analog	NULL
will	NULL
be	NULL
formed	NULL
in	NULL
parallel	NULL
with	NULL
alkyl	NULL
azPC	NULL
during	NULL
LDL	NULL
oxidation	NULL
(	NULL
40	NULL
)	NULL
and	NULL
in	NULL
about	NULL
200-fold	NULL
greater	NULL
abundance	NULL
(	NULL
22	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
results	NULL
with	NULL
phospholipase	NULL
A	NULL
;	NULL
show	NULL
this	NULL
numerical	NULL
advantage	NULL
still	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
contribute	NULL
to	NULL
PPARy	NULL
activation	NULL
by	NULL
oxidized	NULL
LDL	NULL
.	NULL

When	NULL
considering	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
sm-1	NULL
bond	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
commercial	NULL
preparations	NULL
of	NULL
lysophosphatidylcholines	NULL
,	NULL
used	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
diacyl	NULL
phosphatidylcholines	NULL
with	NULL
specific	NULL
sn-2	NULL
residues	NULL
,	NULL
are	NULL
variably	NULL
contaminated	NULL
with	NULL
alkyl	NULL
species	NULL
.	NULL
``	NULL

This	NULL
can	NULL
contribute	NULL
to	NULL
the	NULL
apparent	NULL
activation	NULL
of	NULL
PPARy	NULL
by	NULL
oxidized	NULL
synthetic	NULL
diacyl	NULL
phosphatidylcholines	NULL
,	NULL
so	NULL
the	NULL
material	NULL
we	NULL
used	NULL
to	NULL
synthesize	NULL
the	NULL
diacyl	NULL
homolog	NULL
of	NULL
azPC	NULL
was	NULL
first	NULL
2	NULL
G.	NULL
K.	NULL
Marathe	NULL
A.	NULL
Silva	NULL
,	NULL
H.	NULL
C.	NULL
C.	NULL
F.	NULL
Neto	NULL
,	NULL
L.	NULL
W.	NULL
T.	NULL
Joelker	NULL
,	NULL
S.	NULL
M.	NULL
Prescott	NULL
,	NULL
G.	NULL
A.	NULL
Zimmerman	NULL
,	NULL
and	NULL
T.	NULL
M.	NULL
Mcintyre	NULL
,	NULL
submitted	NULL
for	NULL
publication	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
16022	NULL
a	NULL
10	NULL
£	NULL
8	NULL
x	NULL
o	NULL
A	NULL
6	NULL
C	NULL
T	NULL
C	NULL
S	NULL
4	NULL
0	NULL
m	NULL
2.	NULL
i	NULL
C	NULL
c	NULL
None	NULL
_	NULL
azPC	NULL
oxLDL	NULL
PAF	NULL
anti-CD36	NULL
1gG2c	NULL
Fxn	NULL
6	NULL
b	NULL
a	NULL
4	NULL
DACOX	NULL
1	NULL
ACox	NULL
+	NULL
5	NULL
Danti—Cosﬁ	NULL
3+	NULL
3	NULL
k-	NULL
]	NULL
£	NULL
k-	NULL
]	NULL
£	NULL
*I	NULL
u	NULL
4	NULL
8	NULL
c	NULL
)	NULL
E	NULL
11	NULL
6	NULL
2	NULL
G	NULL
0	NULL
Neg	NULL
Rosi	NULL
azPC	NULL
OxPL	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

CD36	NULL
aids	NULL
azPC	NULL
accumulation	NULL
and	NULL
induction	NULL
of	NULL
ACox	NULL
PPRE-driven	NULL
transcription	NULL
.	NULL

a	NULL
,	NULL
[	NULL
°H	NULL
]	NULL
azPC	NULL
accumulation	NULL
is	NULL
blocked	NULL
by	NULL
anti-CD86	NULL
antibody	NULL
.	NULL

Monocytes	NULL
were	NULL
incubated	NULL
with	NULL
[	NULL
°HJazPC	NULL
for	NULL
30	NULL
min	NULL
without	NULL
or	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
stated	NULL
lipids	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
pM	NULL
.	NULL

Some	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
10	NULL
ug/ml	NULL
blocking	NULL
185-1G2	NULL
anti-CD36	NULL
antibody	NULL
or	NULL
an	NULL
isotype-matched	NULL
IgG2a	NULL
control	NULL
antibody	NULL
.	NULL

6	NULL
,	NULL
inhibition	NULL
of	NULL
CD86	NULL
function	NULL
inhibits	NULL
azPC-induced	NULL
PPRE-controlled	NULL
luciferase	NULL
expression	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
ACox-luciferase	NULL
and	NULL
SV40-G-galactosidase	NULL
as	NULL
above	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
the	NULL
CD36	NULL
blocking	NULL
antibody	NULL
185-1G2Z	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
1	NULL
uM	NULL
rosiglitazone	NULL
(	NULL
Rosi	NULL
)	NULL
,	NULL
azPC	NULL
,	NULL
or	NULL
intact	NULL
oxidized	NULL
LDL	NULL
particles	NULL
.	NULL

The	NULL
fold	NULL
induction	NULL
of	NULL
the	NULL
normalized	NULL
luciferase	NULL
to	NULL
B-galactosidase	NULL
was	NULL
determined	NULL
as	NULL
before	NULL
,	NULL
and	NULL
this	NULL
experiment	NULL
represents	NULL
the	NULL
results	NULL
of	NULL
an	NULL
independent	NULL
experiment	NULL
.	NULL

Oxidized	NULL
Phospholipids	NULL
Are	NULL
PPARy	NULL
Ligands	NULL
purified	NULL
to	NULL
avoid	NULL
this	NULL
spurious	NULL
effect	NULL
.	NULL

Oxidation	NULL
of	NULL
LDL	NULL
creates	NULL
phosphatidylcholines	NULL
with	NULL
fragmented	NULL
s	NULL
»	NULL
-2	NULL
residues	NULL
,	NULL
some	NULL
with	NULL
an	NULL
«	NULL
-carboxylate	NULL
function	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

These	NULL
oxidation	NULL
products	NULL
are	NULL
found	NULL
in	NULL
human	NULL
plasma	NULL
(	NULL
42	NULL
)	NULL
and	NULL
atherosclerotic	NULL
lesions	NULL
(	NULL
43	NULL
)	NULL
.	NULL

PPARy	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
PPARa	NULL
,	NULL
is	NULL
aberrantly	NULL
expressed	NULL
in	NULL
atherosclerotic	NULL
lesions	NULL
(	NULL
20	NULL
)	NULL
and	NULL
co-lonic	NULL
tumors	NULL
(	NULL
44	NULL
)	NULL
,	NULL
which	NULL
provide	NULL
phospholipid	NULL
oxidation	NULL
products	NULL
with	NULL
the	NULL
potential	NULL
to	NULL
alter	NULL
the	NULL
complement	NULL
of	NULL
genes	NULL
expressed	NULL
in	NULL
such	NULL
areas	NULL
.	NULL

Certain	NULL
synthetic	NULL
diacyl	NULL
phospholipid	NULL
oxidation	NULL
products	NULL
modestly	NULL
activate	NULL
PPARa	NULL
function	NULL
(	NULL
12	NULL
)	NULL
.	NULL

However	NULL
,	NULL
PPARa	NULL
activation	NULL
by	NULL
oxidized	NULL
phospholipids	NULL
depends	NULL
on	NULL
phospholipase	NULL
A	NULL
,	NULL
activity	NULL
(	NULL
13	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
oxidized	NULL
free	NULL
fatty	NULL
acid	NULL
products	NULL
of	NULL
this	NULL
reaction	NULL
are	NULL
the	NULL
actual	NULL
ligands	NULL
for	NULL
PPARa	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
we	NULL
show	NULL
PPARy	NULL
to	NULL
directly	NULL
bind	NULL
intact	NULL
,	NULL
and	NULL
only	NULL
intact	NULL
,	NULL
oxidized	NULL
phospholipid	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
azPC	NULL
to	NULL
drive	NULL
PPRE-reporter	NULL
constructs	NULL
at	NULL
submicromolar	NULL
concentrations	NULL
shows	NULL
that	NULL
it	NULL
readily	NULL
crosses	NULL
cellular	NULL
membranes	NULL
,	NULL
apparently	NULL
with	NULL
minimal	NULL
metabolism	NULL
,	NULL
to	NULL
selectively	NULL
activate	NULL
this	NULL
nuclear	NULL
receptor	NULL
.	NULL

Uptake	NULL
of	NULL
the	NULL
intact	NULL
phospholipid	NULL
was	NULL
a	NULL
property	NULL
of	NULL
CD36	NULL
.	NULL

CD36	NULL
is	NULL
a	NULL
type	NULL
B	NULL
scavenger	NULL
receptor	NULL
that	NULL
can	NULL
account	NULL
for	NULL
up	NULL
to	NULL
half	NULL
the	NULL
binding	NULL
,	NULL
internalization	NULL
,	NULL
and	NULL
degradation	NULL
of	NULL
oxidized	NULL
LDL	NULL
by	NULL
human	NULL
macrophages	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
this	NULL
receptor	NULL
is	NULL
induced	NULL
by	NULL
PPARqy	NULL
agonists	NULL
in	NULL
oxidized	NULL
LDL	NULL
(	NULL
10	NULL
,	NULL
18	NULL
)	NULL
.	NULL

CD36	NULL
recognizes	NULL
the	NULL
lipid	NULL
portion	NULL
of	NULL
oxidized	NULL
LDL	NULL
(	NULL
45	NULL
)	NULL
,	NULL
and	NULL
diacyl-oxidized	NULL
phospholipids	NULL
interfere	NULL
with	NULL
this	NULL
uptake	NULL
(	NULL
21	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
CD36	NULL
binds	NULL
phosphatidylcholine	NULL
oxidation	NULL
products	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
it	NULL
also	NULL
internalized	NULL
at	NULL
least	NULL
one	NULL
of	NULL
them	NULL
,	NULL
and	NULL
we	NULL
find	NULL
that	NULL
azPC	NULL
induction	NULL
of	NULL
nuclear	NULL
transcription	NULL
from	NULL
the	NULL
PPRE	NULL
reporter	NULL
was	NULL
CD36-dependent	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
synthetic	NULL
oxidized	NULL
phosphatidylcholine	NULL
was	NULL
transported	NULL
as	NULL
an	NULL
intact	NULL
molecule	NULL
because	NULL
any	NULL
hydrolysis	NULL
and	NULL
resynthesis	NULL
likely	NULL
would	NULL
have	NULL
generated	NULL
the	NULL
inactive	NULL
diacyl	NULL
species	NULL
from	NULL
cellular	NULL
lysophosphatidylcholine	NULL
.	NULL

We	NULL
determined	NULL
whether	NULL
azPC	NULL
uptake	NULL
was	NULL
limiting	NULL
using	NULL
TTA	NULL
,	NULL
a	NULL
lipophilic	NULL
tridentate	NULL
phosphate	NULL
chelator	NULL
(	NULL
25	NULL
)	NULL
that	NULL
increases	NULL
the	NULL
rate	NULL
of	NULL
anionic	NULL
phospholipid	NULL
flip-flop	NULL
across	NULL
unila-mellar	NULL
vesicles	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Our	NULL
experiments	NULL
represent	NULL
the	NULL
first	NULL
use	NULL
of	NULL
this	NULL
class	NULL
of	NULL
agents	NULL
in	NULL
living	NULL
cells	NULL
,	NULL
and	NULL
we	NULL
found	NULL
TTA	NULL
to	NULL
double	NULL
reporter	NULL
expression	NULL
by	NULL
azPC	NULL
or	NULL
intact	NULL
oxidized	NULL
LDL	NULL
.	NULL

There	NULL
were	NULL
two	NULL
notable	NULL
results	NULL
here	NULL
.	NULL

One	NULL
was	NULL
that	NULL
the	NULL
effectiveness	NULL
of	NULL
.	NULL

AzPC	NULL
®	NULL
£	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

The	NULL
flippase	NULL
mimetic	NULL
TTA	NULL
g.	NULL
I	NULL
N	NULL
(	NULL
CHa	NULL
)	NULL
a	NULL
modestly	NULL
improves	NULL
azPC	NULL
induction	NULL
of	NULL
-X	NULL
ik	NULL
e	NULL
PPRE	NULL
reporter	NULL
expression	NULL
.	NULL

a	NULL
,	NULL
TTA	NULL
”	NULL
Ck/NH	NULL
``	NULL
Dig	NULL
complexed	NULL
with	NULL
azPC	NULL
.	NULL

The	NULL
proposed	NULL
interaction	NULL
of	NULL
TTA	NULL
and	NULL
azPC	NULL
is	NULL
based	NULL
on	NULL
the	NULL
proposed	NULL
interaction	NULL
with	NULL
lipid	NULL
phos-phodiesters	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

TTA	NULL
transports	NULL
anionic	NULL
phospholipids	NULL
across	NULL
membrane	NULL
bi-	NULL
a-layers	NULL
(	NULL
24	NULL
)	NULL
and	NULL
should	NULL
circumvent	NULL
cellular	NULL
transport	NULL
mechanisms	NULL
.	NULL

b	NULL
,	NULL
TTA	NULL
affects	NULL
azPC-induced	NULL
gene	NULL
expression	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
ACox-luciferase	NULL
reporter	NULL
and	NULL
stimulated	NULL
with	NULL
200	NULL
nM	NULL
azPC	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

This	NULL
fixed	NULL
amount	NULL
of	NULL
azPC	NULL
was	NULL
preincubated	NULL
with	NULL
the	NULL
stated	NULL
concentration	NULL
of	NULL
the	NULL
flippase	NULL
mimetic	NULL
I	NULL
(	NULL
TTA	NULL
)	NULL
,	NULL
and	NULL
its	NULL
effect	NULL
on	NULL
activa-	NULL
&	NULL
Mat	NULL
»	NULL
(	NULL
RXR	NULL
.	NULL

is	NULL
-*~	NULL
(	NULL
__Gene	NULL
5	NULL
,	NULL
Flippase	NULL
Mimetic	NULL
I	NULL
tion	NULL
of	NULL
the	NULL
ACox-luciferase	NULL
reporter	NULL
was	NULL
5	NULL
then	NULL
determined	NULL
as	NULL
above	NULL
.	NULL

c	NULL
,	NULL
TTA	NULL
improves	NULL
azPC	NULL
and	NULL
intact	NULL
oxidized	NULL
LDL	NULL
induction	NULL
of	NULL
ACox-luciferase	NULL
expression	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
ACox-luciferase	NULL
reporter	NULL
and	NULL
treated	NULL
with	NULL
200	NULL
nM	NULL
azPC	NULL
or	NULL
an	NULL
equivalent	NULL
amount	NULL
of	NULL
oxidized	NULL
LDL	NULL
with	NULL
or	NULL
without	NULL
the	NULL
addition	NULL
of	NULL
10	NULL
um	NULL
TTA	NULL
.	NULL

Luciferase	NULL
was	NULL
assayed	NULL
as	NULL
A-Cox	NULL
Luciferase	NULL
D	NULL
Agonist	NULL
30	NULL
[	NULL
Z	NULL
]	NULL
+	NULL
Flippase	NULL
20	NULL
(	NULL
RLU	NULL
x	NULL
103	NULL
)	NULL
10	NULL
before	NULL
,	NULL
and	NULL
an	NULL
independent	NULL
experiment	NULL
0	NULL
confirmed	NULL
these	NULL
findings	NULL
.	NULL

0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
ACox-luciferase	NULL
Induction	NULL
o	NULL
Buffer	NULL
azPC	NULL
oxLDL	NULL
Flippase	NULL
I	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Oxidized	NULL
Phospholipids	NULL
Are	NULL
PPARy	NULL
Ligands	NULL
azPC	NULL
was	NULL
enhanced	NULL
by	NULL
the	NULL
flippase	NULL
mimetic	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
azPC	NULL
,	NULL
and	NULL
lipids	NULL
in	NULL
oxidized	NULL
LDL	NULL
,	NULL
directly	NULL
activates	NULL
PPARy	NULL
rather	NULL
than	NULL
some	NULL
secondary	NULL
intracellular	NULL
messenger	NULL
produced	NULL
after	NULL
an	NULL
initial	NULL
interaction	NULL
of	NULL
azPC	NULL
with	NULL
an	NULL
unknown	NULL
surface	NULL
receptor	NULL
.	NULL

The	NULL
second	NULL
key	NULL
observation	NULL
was	NULL
that	NULL
TTA	NULL
only	NULL
doubled	NULL
reporter	NULL
activity	NULL
.	NULL

If	NULL
cellular	NULL
uptake	NULL
of	NULL
exogenous	NULL
azPC	NULL
had	NULL
been	NULL
severely	NULL
limiting	NULL
,	NULL
then	NULL
circumventing	NULL
this	NULL
step	NULL
should	NULL
have	NULL
markedly	NULL
enhanced	NULL
reporter	NULL
induction	NULL
.	NULL

Since	NULL
it	NULL
did	NULL
not	NULL
,	NULL
it	NULL
is	NULL
fair	NULL
to	NULL
conclude	NULL
that	NULL
azPC	NULL
entry	NULL
into	NULL
cells	NULL
is	NULL
relatively	NULL
efficient	NULL
.	NULL

Oxidative	NULL
stress	NULL
arises	NULL
from	NULL
a	NULL
number	NULL
of	NULL
sources	NULL
,	NULL
from	NULL
exuberant	NULL
inflammatory	NULL
reactions	NULL
to	NULL
ionizing	NULL
radiation	NULL
.	NULL

Reactive	NULL
oxygen	NULL
species	NULL
and	NULL
the	NULL
oxidized	NULL
LDL	NULL
generated	NULL
by	NULL
them	NULL
are	NULL
postulated	NULL
to	NULL
initiate	NULL
and	NULL
maintain	NULL
an	NULL
inflammatory	NULL
state	NULL
in	NULL
the	NULL
vascular	NULL
wall	NULL
during	NULL
atherogenesis	NULL
(	NULL
46-48	NULL
)	NULL
.	NULL

LDL	NULL
oxidized	NULL
ex	NULL
vivo	NULL
,	NULL
like	NULL
the	NULL
oxidized	NULL
particles	NULL
obtained	NULL
from	NULL
atherosclerotic	NULL
plaques	NULL
(	NULL
49	NULL
)	NULL
,	NULL
contains	NULL
inflammatory	NULL
lipids	NULL
that	NULL
increase	NULL
the	NULL
atherogenicity	NULL
of	NULL
these	NULL
particles	NULL
.	NULL

Similarly	NULL
,	NULL
oxidized	NULL
LDL	NULL
in	NULL
the	NULL
circulation	NULL
(	NULL
42	NULL
,	NULL
50	NULL
)	NULL
or	NULL
in	NULL
atherosclerotic	NULL
plaques	NULL
(	NULL
43	NULL
)	NULL
also	NULL
contains	NULL
fragmented	NULL
and	NULL
oxidatively	NULL
modified	NULL
phospholipids	NULL
(	NULL
26	NULL
,	NULL
40	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
are	NULL
agonists	NULL
for	NULL
the	NULL
PAF	NULL
receptor	NULL
(	NULL
27	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
others	NULL
are	NULL
high	NULL
affinity	NULL
ligands	NULL
and	NULL
activators	NULL
of	NULL
PPARy	NULL
.	NULL

This	NULL
establishes	NULL
a	NULL
new	NULL
link	NULL
connecting	NULL
LDL	NULL
oxidation	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
PPAR-regulated	NULL
genes	NULL
,	NULL
and	NULL
oxidized	NULL
LDL	NULL
(	NULL
52	NULL
)	NULL
,	NULL
fragmented	NULL
phospholipids	NULL
(	NULL
43	NULL
)	NULL
,	NULL
monocytes	NULL
(	NULL
53	NULL
)	NULL
,	NULL
and	NULL
PPARy	NULL
(	NULL
20	NULL
)	NULL
are	NULL
all	NULL
present	NULL
in	NULL
atherosclerotic	NULL
lesions	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Elizabeth	NULL
Meade	NULL
for	NULL
supplying	NULL
the	NULL
acyl-CoA	NULL
oxidase-luciferase	NULL
reporter	NULL
,	NULL
pCR2.1-PPARy	NULL
,	NULL
and	NULL
pCR2.1-PPARa	NULL
.	NULL

We	NULL
thank	NULL
Clare	NULL
Amann	NULL
and	NULL
Anna	NULL
Pavlovic	NULL
of	NULL
the	NULL
University	NULL
of	NULL
Utah	NULL
Chemical	NULL
Synthesis	NULL
Facility	NULL
for	NULL
the	NULL
synthesis	NULL
and	NULL
analysis	NULL
of	NULL
azelaic	NULL
anhydride	NULL
and	NULL
Andrew	NULL
Maxfield	NULL
for	NULL
aid	NULL
with	NULL
the	NULL
synthesis	NULL
of	NULL
TTA	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Diana	NULL
Lim	NULL
for	NULL
figure	NULL
preparation	NULL
.	NULL

The	NULL
University	NULL
of	NULL
Utah	NULL
DNA	NULL
Synthesis	NULL
and	NULL
Analysis	NULL
core	NULL
facility	NULL
and	NULL
the	NULL
Flow	NULL
cytom-etry	NULL
core	NULL
facility	NULL
were	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
funds	NULL
from	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
P30	NULL
CA	NULL
42014	NULL
.	NULL

REFERENCES	NULL
.	NULL

Desvergne	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Wahli	NULL
,	NULL
W.	NULL
(	NULL
1999	NULL
)	NULL
Endocr	NULL
.	NULL

Rev	NULL
.	NULL

20	NULL
,	NULL
649-688	NULL
.	NULL

Forman	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Tontonoz	NULL
,	NULL
P.	NULL
,	NULL
Chen	NULL
,	NULL
J.	NULL
,	NULL
Brun	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Spiegelman	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
838	NULL
,	NULL
803-812	NULL
8	NULL
.	NULL

Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Lenbard	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Wilson	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Patel	NULL
,	NULL
I.	NULL
,	NULL
Morris	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
and	NULL
Lehmann	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
88	NULL
,	NULL
813-819	NULL
4	NULL
.	NULL

Lenz	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Hughes	NULL
,	NULL
H.	NULL
,	NULL
Mitchell	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Via	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
Guyton	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Taylor	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Gotto	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
C.	NULL
V.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Lipid	NULL
Res	NULL
.	NULL

81	NULL
,	NULL
1043-1050	NULL
5	NULL
.	NULL

Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Sundseth	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Jones	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Brown	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Wisely	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
Koble	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Devchand	NULL
,	NULL
P.	NULL
,	NULL
Wahli	NULL
,	NULL
W.	NULL
,	NULL
Willson	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Lenhard	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Lehmann	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

94	NULL
,	NULL
4818-4323	NULL
6	NULL
.	NULL

Forman	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Chen	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

94	NULL
,	NULL
4312-4317	NULL
.	NULL

Spiegelman	NULL
,	NULL
B.	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
98	NULL
,	NULL
153-155	NULL
.	NULL

Folcik	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
and	NULL
Cathcart	NULL
,	NULL
M.	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Lipid	NULL
Res	NULL
.	NULL

85	NULL
,	NULL
1570-1582	NULL
.	NULL

Beckman	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Bagheri	NULL
,	NULL
F.	NULL
,	NULL
Ji	NULL
,	NULL
C.	NULL
,	NULL
Blair	NULL
,	NULL
I	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Marnett	NULL
,	NULL
L.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Carcinogenesis	NULL
15	NULL
,	NULL
2937-2944	NULL
10	NULL
.	NULL

Nagy	NULL
,	NULL
L.	NULL
,	NULL
Tontonoz	NULL
,	NULL
P.	NULL
,	NULL
Alvarez	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Chen	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
93	NULL
,	NULL
229-240	NULL
11	NULL
.	NULL

Maxey	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Hessler	NULL
,	NULL
E.	NULL
,	NULL
MacDonald	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Hitchingham	NULL
,	NULL
L.	NULL
(	NULL
2000	NULL
)	NULL
Pros-taglandins	NULL
Other	NULL
Lipid	NULL
Mediat	NULL
.	NULL

62	NULL
,	NULL
15-21	NULL
12	NULL
.	NULL

Lee	NULL
,	NULL
H.	NULL
,	NULL
Shi	NULL
,	NULL
W.	NULL
,	NULL
Tontonoz	NULL
,	NULL
P.	NULL
,	NULL
Wang	NULL
,	NULL
S.	NULL
,	NULL
Subbanagounder	NULL
,	NULL
G.	NULL
,	NULL
Hedrick	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Hama	NULL
,	NULL
S.	NULL
,	NULL
Borromeo	NULL
,	NULL
C.	NULL
,	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Berliner	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Nagy	NULL
,	NULL
L.	NULL
(	NULL
2000	NULL
)	NULL
Circ	NULL
.	NULL

Res	NULL
.	NULL

87	NULL
,	NULL
516-521	NULL
13	NULL
.	NULL

Delerive	NULL
,	NULL
P.	NULL
,	NULL
Furman	NULL
,	NULL
C.	NULL
,	NULL
Teissier	NULL
,	NULL
E.	NULL
,	NULL
Fruchart	NULL
,	NULL
J.	NULL
,	NULL
Duriez	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Staels	NULL
,	NULL
B	NULL
.	NULL

(	NULL
2000	NULL
)	NULL
FEBS	NULL
Lett	NULL
.	NULL

471	NULL
,	NULL
34-38	NULL
14	NULL
.	NULL

Fruchart	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Duriez	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Staels	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Lipidol	NULL
.	NULL

10	NULL
,	NULL
245-257	NULL
15	NULL
.	NULL

Poynter	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
and	NULL
Daynes	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
82838-82841	NULL
16	NULL
.	NULL

Auwerx	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
Diabetologia	NULL
42	NULL
,	NULL
1033-1049	NULL
17	NULL
.	NULL

Tontonoz	NULL
,	NULL
P.	NULL
,	NULL
Nagy	NULL
,	NULL
L.	NULL
,	NULL
Alvarez	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Thomazy	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
N	NULL
1	NULL
t	NULL
go	NULL
si	NULL
18	NULL
19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

16023	NULL
Cell	NULL
98	NULL
,	NULL
241-252	NULL
.	NULL

Feng	NULL
,	NULL
J.	NULL
,	NULL
Han	NULL
,	NULL
J.	NULL
,	NULL
Pearce	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
Silverstein	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Gotto	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Jr.	NULL
,	NULL
Hajjar	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
and	NULL
Nicholson	NULL
,	NULL
A.	NULL
C.	NULL
(	NULL
2000	NULL
)	NULL
J.	NULL
Lipid	NULL
Res	NULL
.	NULL

41	NULL
,	NULL
688-696	NULL
Marx	NULL
,	NULL
N.	NULL
,	NULL
Sukhova	NULL
,	NULL
G.	NULL
,	NULL
Murphy	NULL
,	NULL
C.	NULL
,	NULL
Libby	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Plutzky	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

158	NULL
,	NULL
17-28	NULL
Ricote	NULL
,	NULL
M.	NULL
,	NULL
Huang	NULL
,	NULL
J.	NULL
,	NULL
Fajas	NULL
,	NULL
L.	NULL
,	NULL
Li	NULL
,	NULL
A.	NULL
,	NULL
Welch	NULL
,	NULL
J.	NULL
,	NULL
Najib	NULL
,	NULL
J.	NULL
,	NULL
Witztum	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Auwerx	NULL
,	NULL
J.	NULL
,	NULL
Palinski	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Glass	NULL
,	NULL
C.	NULL
K.	NULL
(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

95	NULL
,	NULL
7614-7619	NULL
Podrez	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Febbraio	NULL
,	NULL
M.	NULL
,	NULL
Sheibani	NULL
,	NULL
N.	NULL
,	NULL
Schmitt	NULL
,	NULL
D.	NULL
,	NULL
Silverstein	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Hajjar	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
Cohen	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Frazier	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Hoff	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
and	NULL
Hazen	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
2000	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

105	NULL
,	NULL
1095-1108	NULL
Diagne	NULL
,	NULL
A.	NULL
,	NULL
Fauvel	NULL
,	NULL
J.	NULL
,	NULL
Record	NULL
,	NULL
M.	NULL
,	NULL
Chap	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Douste-Blazy	NULL
,	NULL
L.	NULL
(	NULL
1984	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
798	NULL
,	NULL
221-231	NULL
Armesilla	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
and	NULL
Vega	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
18985-18991	NULL
Boon	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
B.	NULL
D.	NULL
(	NULL
1999	NULL
)	NULL
J	NULL
.	NULL

Am	NULL
.	NULL

Chem	NULL
.	NULL

Soc	NULL
.	NULL

121	NULL
,	NULL
11924-11925	NULL
Valiyaveeettil	NULL
,	NULL
S.	NULL
,	NULL
Engbersen	NULL
,	NULL
J.	NULL
F.	NULL
J.	NULL
,	NULL
Verboom	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Reinhoudt	NULL
,	NULL
D.	NULL
N.	NULL
(	NULL
1993	NULL
)	NULL
Angew	NULL
.	NULL

Chem	NULL
.	NULL

Int	NULL
.	NULL

Ed	NULL
.	NULL

Engl	NULL
.	NULL

82	NULL
,	NULL
900-901	NULL
Heery	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Kozak	NULL
,	NULL
M.	NULL
,	NULL
Stafforini	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Jones	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Melntyre	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
and	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

96	NULL
,	NULL
2322-2330	NULL
Marathe	NULL
,	NULL
G.	NULL
K.	NULL
,	NULL
Davies	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Harrison	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Silva	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Murphy	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Castro-Faria	NULL
Neto	NULL
,	NULL
H.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
and	NULL
Mcintyre	NULL
,	NULL
T.	NULL
M.	NULL
(	NULL
1999	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274	NULL
,	NULL
28395-28405	NULL
Ames	NULL
,	NULL
B.	NULL
N.	NULL
,	NULL
and	NULL
Dubin	NULL
,	NULL
D.	NULL
T.	NULL
(	NULL
1960	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

285	NULL
,	NULL
769-775	NULL
Elstad	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Mcintyre	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
and	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
1618-1624	NULL
Kessel	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Hayflick	NULL
,	NULL
J.	NULL
,	NULL
Weyrich	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Hoffman	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Gallatin	NULL
,	NULL
M.	NULL
,	NULL
Melntyre	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

160	NULL
,	NULL
5579-5587	NULL
Meade	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Mcintyre	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
and	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
(	NULL
1999	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274	NULL
,	NULL
8328-8884	NULL
Kayganich-Harrison	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
Murphy	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

221	NULL
,	NULL
16-24	NULL
Lehmann	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Moore	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
Smith-Oliver	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Wilkison	NULL
,	NULL
W.	NULL
O.	NULL
,	NULL
Willson	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
and	NULL
Kliewer	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
12953-12956	NULL
Shao	NULL
,	NULL
D.	NULL
,	NULL
Rangwala	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Bailey	NULL
,	NULL
S.	NULL
T.	NULL
,	NULL
Krakow	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Reginato	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Lazar	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Nature	NULL
896	NULL
,	NULL
877-380	NULL
Nolte	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Wisely	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
Westin	NULL
,	NULL
S.	NULL
,	NULL
Cobb	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Lambert	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Kurokawa	NULL
,	NULL
R.	NULL
,	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Willson	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Glass	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
and	NULL
Milburn	NULL
,	NULL
M.	NULL
V.	NULL
(	NULL
1998	NULL
)	NULL
Nature	NULL
895	NULL
,	NULL
137-143	NULL
Gampe	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Montana	NULL
,	NULL
V.	NULL
G.	NULL
,	NULL
Lambert	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Miller	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
Bledsoe	NULL
,	NULL
R.	NULL
K.	NULL
,	NULL
Milburn	NULL
,	NULL
M.	NULL
V.	NULL
,	NULL
Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Wilson	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
and	NULL
Xu	NULL
,	NULL
H.	NULL
E.	NULL
(	NULL
2000	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
5	NULL
,	NULL
b45-555	NULL
Schulman	NULL
,	NULL
I.	NULL
G.	NULL
,	NULL
Li	NULL
,	NULL
C.	NULL
,	NULL
Schwabe	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

11	NULL
,	NULL
299-308	NULL
Young	NULL
,	NULL
P.	NULL
W.	NULL
,	NULL
Buckle	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Cantello	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
Chapman	NULL
,	NULL
H.	NULL
,	NULL
Clapham	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Coyle	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Haigh	NULL
,	NULL
D.	NULL
,	NULL
Hindley	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Holder	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Kallender	NULL
,	NULL
H.	NULL
,	NULL
Latter	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Lawrie	NULL
,	NULL
K.	NULL
W.	NULL
M.	NULL
,	NULL
Mossakowska	NULL
,	NULL
D.	NULL
,	NULL
Murphy	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Roxbee	NULL
Cox	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

284	NULL
,	NULL
751-759	NULL
Reginato	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Bailey	NULL
,	NULL
S.	NULL
T.	NULL
,	NULL
Krakow	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Minami	NULL
,	NULL
C.	NULL
,	NULL
Ishii	NULL
,	NULL
S.	NULL
,	NULL
Tanaka	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Lazar	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
82679-82684	NULL
Tokumura	NULL
,	NULL
A.	NULL
,	NULL
Toujima	NULL
,	NULL
M.	NULL
,	NULL
Yoshioka	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Fukuzawa	NULL
,	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
Lipids	NULL
31	NULL
,	NULL
1251-1258	NULL
Stremler	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Stafforini	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
McIntyre	NULL
,	NULL
T.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
11095-11103	NULL
Schlame	NULL
,	NULL
M.	NULL
,	NULL
Haupt	NULL
,	NULL
R.	NULL
,	NULL
Wiswedel	NULL
,	NULL
L.	NULL
,	NULL
Kox	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
and	NULL
Rustow	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Lipid	NULL
Res	NULL
.	NULL

87	NULL
,	NULL
2608-2615	NULL
Watson	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Leitinger	NULL
,	NULL
N.	NULL
,	NULL
Navab	NULL
,	NULL
M.	NULL
,	NULL
Faull	NULL
,	NULL
K.	NULL
F.	NULL
,	NULL
Horkko	NULL
,	NULL
S.	NULL
,	NULL
Witztum	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Palinski	NULL
,	NULL
W.	NULL
,	NULL
Schwenke	NULL
,	NULL
D.	NULL
,	NULL
Salomon	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
Sha	NULL
,	NULL
W.	NULL
,	NULL
Subbanagounder	NULL
,	NULL
G.	NULL
,	NULL
Fogelman	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
Berliner	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
13597-13560.7	NULL
DuBois	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
Gupta	NULL
,	NULL
R.	NULL
,	NULL
Brockman	NULL
,	NULL
J.	NULL
,	NULL
Reddy	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
Krakow	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Lazar	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Carcinogenesis	NULL
19	NULL
,	NULL
49-53	NULL
Nicholson	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Frieda	NULL
,	NULL
S.	NULL
,	NULL
Pearce	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Silverstein	NULL
,	NULL
R.	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

Vase	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
269-275	NULL
Glavind	NULL
,	NULL
J.	NULL
,	NULL
Hartmann	NULL
,	NULL
S.	NULL
,	NULL
Clemmensen	NULL
,	NULL
J.	NULL
,	NULL
Jessen	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
and	NULL
Dam	NULL
,	NULL
H.	NULL
(	NULL
1952	NULL
)	NULL
Acta	NULL
Pathol	NULL
.	NULL

Microbiol	NULL
.	NULL

Scand	NULL
.	NULL

80	NULL
,	NULL
1-6	NULL
Yagi	NULL
,	NULL
K.	NULL
(	NULL
1984	NULL
)	NULL
BioEssays	NULL
1	NULL
,	NULL
58-60	NULL
Steinberg	NULL
,	NULL
D.	NULL
,	NULL
Parthasarathy	NULL
,	NULL
S.	NULL
,	NULL
Carew	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
Khoo	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Witztum	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

820	NULL
,	NULL
915-924	NULL
Hoff	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
and	NULL
O'Neil	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

11	NULL
,	NULL
1209-1222	NULL
Lebr	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Weyrich	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Sactzler	NULL
,	NULL
R.	NULL
K.	NULL
,	NULL
Jurek	NULL
,	NULL
A.	NULL
,	NULL
Arfors	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Mclntyre	NULL
,	NULL
T.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

99	NULL
,	NULL
2358-2364	NULL
MeclIntyre	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
and	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
(	NULL
1999	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274	NULL
,	NULL
25189-25192	NULL
Vla-Herttuala	NULL
,	NULL
S.	NULL
,	NULL
Palinski	NULL
,	NULL
W.	NULL
,	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Parthasarathy	NULL
,	NULL
S.	NULL
,	NULL
Carew	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
Butler	NULL
,	NULL
S.	NULL
,	NULL
Witztum	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Steinberg	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

84	NULL
,	NULL
1086-1095	NULL
Vla-Herttuala	NULL
,	NULL
S.	NULL
,	NULL
Lipton	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Sarkioja	NULL
,	NULL
T.	NULL
,	NULL
Yoshimura	NULL
,	NULL
T.	NULL
,	NULL
Leonard	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Witztum	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Steinberg	NULL
,	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
5252-5256	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Oxidized	NULL
Alkyl	NULL
Phospholipids	NULL
Are	NULL
Specific	NULL
,	NULL
High	NULL
Affinity	NULL
Peroxisome	NULL
Proliferator-activated	NULL
Receptor	NULL
y	NULL
Ligands	NULL
and	NULL
Agonists	NULL
Sean	NULL
S.	NULL
Davies	NULL
,	NULL
Aaron	NULL
V.	NULL
Pontsler	NULL
,	NULL
Gopal	NULL
K.	NULL
Marathe	NULL
,	NULL
Kathleen	NULL
A.	NULL
Harrison	NULL
,	NULL
Robert	NULL
C.	NULL
Murphy	NULL
,	NULL
Jerald	NULL
C.	NULL
Hinshaw	NULL
,	NULL
Glenn	NULL
D.	NULL
Prestwich	NULL
,	NULL
Andy	NULL
St.	NULL
Hilaire	NULL
,	NULL
Stephen	NULL
M.	NULL
Prescott	NULL
,	NULL
Guy	NULL
A.	NULL
Zimmerman	NULL
and	NULL
Thomas	NULL
M.	NULL
McIntyre	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

2001	NULL
,	NULL
276:16015-16023.	NULL
doi	NULL
:	NULL
10.1074/jbc.M100878200	NULL
originally	NULL
published	NULL
online	NULL
February	NULL
26	NULL
,	NULL
2001	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
doi	NULL
:	NULL
10.1074/jbe.M100878200	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
53	NULL
references	NULL
,	NULL
25	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL

